Advanced Gene Therapy Strategies for the Repair of ACL Injuries

Mahnaz Amini 1, Jagadeesh K. Venkatesan 1, Wei Liu 1, Amélie Leroux 2, Tuan Ngoc Nguyen 2, Henning Madry 1, Véronique Migonney 2 and Magali Cucchiarini 1,

1 Center of Experimental Orthopaedics, Saarland University Medical Center, Kirrbergerstr. Bldg 37, D-66421 Homburg, Germany
2 Laboratoire CSPBAT UMR CNRS 7244, Université Sorbonne Paris Nord, Avenue JB Clément, 93430 Villetaneuse, France
* Correspondence: mmcucchiarini@hotmail.com or magali.madry@uks.eu

Abstract: The anterior cruciate ligament (ACL), the principal ligament for stabilization of the knee, is highly predisposed to injury in the human population. As a result of its poor intrinsic healing capacities, surgical intervention is generally necessary to repair ACL lesions, yet the outcomes are never fully satisfactory in terms of long-lasting, complete, and safe repair. Gene therapy, based on the transfer of therapeutic genetic sequences via a gene vector, is a potent tool to durably and adeptly enhance the processes of ACL repair and has been reported for its workability in various experimental models relevant to ACL injuries in vitro, in situ, and in vivo. As critical hurdles to the effective and safe translation of gene therapy for clinical applications still remain, including physiological barriers and host immune responses, biomaterial-guided gene therapy inspired by drug delivery systems has been further developed to protect and improve the classical procedures of gene transfer in the future treatment of ACL injuries in patients, as critically presented here.

Keywords: ACL; injuries; tissue engineering; gene therapy; biomaterial-guided gene transfer

1. Introduction

Injuries in the anterior cruciate ligament (ACL) of the knee are common, representing an important socioeconomical burden as they may occur both in young individuals following sport activities and in the aging population by chronic degeneration and result in diminished musculoskeletal functions and potentially leading to osteoarthritis [1–3]. Since the ACL has a slow and limited intrinsic ability for self-healing [2,4–11], various clinical options have been developed to enhance the reparative activities in sites of ACL injury, including conservative treatments and surgical interventions such as ACL reconstruction [11–22] using natural grafts (auto-/allografts) and synthetic materials [22–29]. Yet, none of these approaches afford the long-lasting healing of ACL lesions with original structural and mechanical features, and they can be associated with notable complications including pain, contractures, weakness, failure, re-ruptures, premature osteoarthritis, infections, and detrimental body responses [17,18,23,30–41].

To address these issues, novel therapeutic strategies were established to improve the mechanisms of ACL repair based on the further use of tissue engineering tools including adapted scaffolds (structural templates), cell-based material (reparative elements), bioreactors (environmental and loading control systems), and biological stimuli (regulatory factors and cues) [2,8,37,42–72], yet application of these systems in experimental settings was met with only limited success and did not allow for full and durable ACL repair.

In this regard, gene therapy may provide adapted tools for an improved, prolonged healing of ACL lesions by transfer of candidate genetic sequences with a gene carrier (vector) to extend the therapeutic activities of the gene products (growth and transcription factors, signaling molecules, therapeutic ribonucleic acids—RNAs) in sites of ACL
In this regard, gene therapy may provide adapted tools for an improved, prolonged action [73–93]. However, clinical gene therapy is still hindered by different physiological barriers in the recipient, including physical obstacles (body fluids, dense joint extracellular matrices) and biological inhibitors (pH/enzymatic environment of the joint, neutralizing host immune responses, rate-limiting intracellular steps, gene dissemination to non-target locations) [83,94–98]. A very innovative approach to tackle these problems is to provide therapeutic gene vectors via biomaterial-guided delivery in sites of ACL injury as an off-the-shelf system, allowing for a safe, stabilized, and protected controlled release of the gene vehicles using biocompatible scaffolds (cargos) [82,83,87,90,99–104]. The goal of this work is, therefore, to provide an overview of the most advanced gene therapy procedures that aim at enhancing the repair of ACL injuries.

2. ACL: Basic Science, Clinical Questions

2.1. ACL Function and Structure

The knee joint contains four ligaments that play key roles in kinematics and maintaining knee stability, connecting bones to each other, including two lateral ligaments that provide stability in the frontal plane and the anterior and posterior cruciate ligaments that support stability in the sagittal plane. Located in the center of the knee, the ACL forms part of the “central pivot” with the posterior cruciate ligament. The ACL is fundamental to connect the anterior part of the tibia to the posterior part of the femur, opposing forward displacement and excessive internal rotation of the tibia relative to the femur and stabilizing the knee during rotational movements [17,105–107] (Figure 1).

![Figure 1. Knee key ligaments](image)

The ACL is a dense, cable-like tissue (27–32 mm in length, 10 mm in breadth, 4–10 mm in width, and 44.4–57.5 mm² cross-sectional area) [46,105,108] that is highly organized, with an abundant extracellular matrix (ECM) mainly composed of collagens in fiber bundles (predominantly type-I collagen and types-III, -IV, -V, and -VI collagens; 70–80% dry weight) with elastin, fibronectin, thrombospondin, and proteoglycans (organization and lubrication of collagen fibril bundles) also surrounding ECM-producing cells (fibroblasts) in a hypocellular structure containing water (55–70%). The ACL has a hierarchical, sequentially assembled organization with increasing diameter and mechanical strength that includes collagen molecules (triple-helix polypeptide chains, <2 nm in diameter) that crosslink to form microfibrils (3.5 nm in diameter) that arrange themselves into subfibrils (10–20 nm in diameter) and then in fibrils (50–500 nm in diameter) that form fibers in fascicles (50–300 µm, with a crimp pattern repeated every 45–60 µm) that mutually crosslink to make a subfascicular unit running parallel to the long axis of the tissue, also containing proteoglycans and elastin and surrounded by a vascularized epiligament sheath to form the ligament [7,45,46,49,105,109–112] (Figure 2).
The cells in the ACL are interspersed between the collagen fibril bundles along the long axis, with a spindle-shaped form at an immature stage and a more elongated shape when they age. The ACL originates from the lateral plate mesoderm and its development is regulated by signaling from various growth factors (transforming growth factor beta—TGF-β—via TGFBR-receptor signaling and small mothers against decapentaplegic proteins—Smads; fibroblast growth factor—FGF—via FGFR-receptor signaling and extracellular signal-regulated kinase—ERK/mitogen-activated protein kinase—MAPK) and transcription factors (scleraxis—SCX—a basic helix-loop-helix factor; Mohawk—MKX—encoded by an atypical, three-amino-acid loop homeobox gene; early growth response factor 1—Egr1—a zinc finger transcription factor) that promote the differentiation of mesenchymal progenitor cells into ligament cells [11,105,113–120] (Figure 3).

![Figure 2](image-url)  
**Figure 2.** Schematic drawing of the multi-unit hierarchical structure of the ligament.

![Figure 3](image-url)  
**Figure 3.** Expression patterns of critical transcription factors during the development of the ACL (SCX, scleraxis; FGF, fibroblast growth factor; TGF-β, transforming growth factor beta; MKX, Mohawk, Egr1, early growth response factor 1).

2.2. Clinical Aspects: Pathology, Natural Healing, and Current Treatments

Ligament injuries are common, especially in the ACL (25–50% of knee ligamentous injuries; incidence of 1 per 3000 inhabitants per year in the United States and in Europe) [1]. ACL injuries are mainly derived from sport activities (65%) in the young population (70% of affected patients between 20–35 years old) and occur via chronic tissue degeneration in the aging population, both resulting in diminished musculoskeletal functions.
and potentially leading to osteoarthritis [1,35]. In the United States only, approximately 300,000 ACL reconstruction surgeries are performed annually, costing approximately USD 30 billion [2,3,10,60], clearly representing a significant public health problem.

The natural healing of ACL injuries is slow and inefficient, leading to the formation of scar tissue that does not naturally reproduce the original biological and mechanical properties of the tissue due to the limited intrinsic ability of the ACL to fully heal [2,4–8,10,11,13–16,46,54,121]. Three major cascade phases of ligament healing have been defined in response to injury, including (1) an inflammatory stage within the first days and weeks of injury (serous fluid accumulation, fragilization of the area, formation of a fibrin clot, invasion by monocytes/leukocytes/macrophages, debris removal, release of pro-angiogenic and proliferative growth factors and cytokines), (2) a proliferative stage by 8 weeks (blood vessel formation, fibroblast proliferation with collagen matrix production to fill up the injury), and (3) a remodeling phase between 1 and 2 years (decrease in cellularity, matrix realignment for adapted response to mechanical forces) [5,8]. The lack of proper ACL healing is due to the intra-articular conditions (synovial fluid, intra-articular movements) that hinder the stable formation of a fibrin/platelet scaffold (a prerequisite to primary healing), to an insufficient availability of reparative factors (growth factors and cytokines, wound filling compounds such as fibrinogen/fibronectin), to the lack of continuity between collagen fibers between the new and the old matrices leading to reduced tissue mechanical properties, and to the absence of vascularization of this ligament [2,5,8,10].

Due to the limited healing capacity of the ACL, a number of therapeutic options have been developed to restore its functions in the knee, including non-operative conservative treatments (immobilization/bracing/rest, exercise/physiotherapy, corticoid injection, etc.) and surgical procedures (ACL reconstruction, i.e., ligamentoplasty), while primary repair (suturing) was abandoned due to high rates of failure (40–100%) [2,11,12,17–23,37,60]. ACL reconstruction has been widely adopted as a standard procedure, especially for young patients, based on the use of both natural/biological grafts including autografts (patellar, hamstring, or quadriceps tendons) and allografts (frozen ligaments from cadavers), as well as commercially available synthetic or artificial materials and systems (substitutes, graft-augmented, and prosthetic devices) (Gore-Tex®—polytetrafluoroethylene—prosthesis; Lars® ligament—terephthalic polyethylene polyester; Stryker-Dacron® ligament—polyethylene terephthalate; Leeds-Keio®—polyester ethylene terephthalate; Kennedy ligament-augmentation device—LAD—braided polypropylene braid) [2,17,18,22–29,37,46,60,105,122]. While autografts display several advantages (good initial mechanical strength, adapted to promote cell proliferation and neotissue formation), their use is restricted by their limited availability, the necessity for second surgery for tissue harvest, the problem of donor site morbidity resulting in pain/contracture/weakness, and a lack of fully adequate mechanical strength over time [2,17,18,22,23,37,46,60]. Regarding allografts instead, second surgery for tissue harvest is not needed and there is no limit to the supply of graft tissue, generally allowing for good initial mechanical strength and supporting cell proliferation and neotissue formation. However, the use of allografts is associated with a possible transmission of diseases and infections, with potential host immunological foreign body responses, delayed biological integration, and a lack of fully adequate mechanical strength over time while their sterilization usually affects their mechanical properties [2,17,18,22,23,37,46,60]. Synthetic or artificial materials and systems have a number of advantages over natural grafts (availability, reproducibility, safety) but they may fail over time as they do not reliably reproduce the mechanical properties of the ACL, potentially leading to permanent deformation and degeneration upon repeated elongation with the creation of inflammatory debris in the joint [2,17,18,22,23,37,46,54,60]. While patients have benefited from ACL reconstruction, a significant percentage of them (20–25%) have unadapted and unsatisfactory outcomes and serious complications over time (7–10 years after surgery), including re-ruptures and premature osteoarthritic changes (50% incidence), both in young active patients and in elder individuals [9,30–34,36,38–41,123].
2.3. Experimental Treatments: Tissue Engineering and Biological Augmentation

As none of the current therapeutic interventions have, thus far, been capable of affording long-lasting ACL repair, other options have been envisaged to manage this critical clinical issue, including tissue engineering procedures and biological augmentation to replicate the natural environment of the ACL tissue and enhance its reparative activities based on the use of (1) biocompatible, biodegradable, minimally inflammatory, and mechanically adapted material scaffolds serving as structural and logistic templates, (2) cells and tissues providing reparative components, (3) bioreactors for loading and as control systems of the cellular environment, and (4) biological, biochemical, and biomechanical signals and nutrients as regulatory factors and cues [2,8,10,11,26,43–49,52,54–57,59–70,72,75,124–149].

Biomaterial scaffolds used for ACL repair include systems (solutions, gels, fibers, membranes, matrices, sponges) based on fibrin [150,151], hyaluronic acid (HA) [152–155], chitosan [156], collagen [44,157–168], silk [169–183], poly(glycolic acid) (PGA) [184–186], poly(lactic acid) (PLA) [186–195], poly(lactic-co-glycolic acid) (PLGA) [42,168,186–188,196–198], poly(caprolactone) (PCL) [199–206], polyurethane (PU) [168], oligo(poly(ethylene glycol) fumarate) (OPF) [207], poly(ethylene terephthalate) (PET) [208–212], and hybrid compounds such as collagen/glycosaminoglycan (GAG) [213,214], collagen/silk [215–217], collagen/poly(desaminotyrosyl-tyrosine dodecyl dodecanedioate) (pDTD DD) [218], silk/PLGA [219], chitosan/HA [220], chitosan/PLA [221], chitosan/PCL [222], PLA/PCL [223], PGA/PCL [184], and PLA/PLGA systems [224], with successful attempts at material functionalization for ACL repair using for instance poly(sodium styrene sulfonate) (polyNaSS) grafting [205,206,209,211] (Table 1).

Table 1. Applications of tissue engineering for ACL repair.

| Scaffolds | Cells | Factors | Bioreactors | Effects | Refs. |
|-----------|-------|---------|-------------|---------|-------|
| fibrin    | -     | -       | -           | improved ACL repair (goats) | [150] |
|           | CTGF  | -       | -           | improved ACL repair (rabbits) | [151] |
| HA        | -     | TGF-β,  | -           | higher cell outgrowth in ACL explants | [154] |
|           |       | FGF-2,  | -           |         |       |
|           |       | PDGF,   | -           |         |       |
|           |       | insulin | -           |         |       |
| MSCs      | -     | -       | -           | higher cell growth, differentiation | [153] |
| chitosan  | ACL fibroblasts | - | - | higher cell adhesion, differentiation | [156] |
| collagen  | ACL, skin fibroblasts | - | - | improved ACL repair (rabbits, pigs) | [157,158,161,162,164] |
|           | MSCs  | -       | +           | higher cell growth, differentiation | [159,160,166,168] |
|           | ASCs  | -       | -           | higher cell growth, differentiation | [165] |
| Scaffolds | Cells | Factors | Bioreactors | Effects | Refs. |
|----------|-------|---------|-------------|---------|-------|
| silk     | ACL, skin fibroblasts | - | - | improved ACL repair (dogs) | [171,178,182] |
| MSCs     | + | higher cell growth, differentiation, improved ACL repair (sheep) | | [169,171,173–177,179,181,183] |
| TGF-β, FGF-2, EGF | - | higher cell growth, differentiation | | [172] |
| PGA      | - | - | - | improved ACL repair (dogs) | [185] |
| ACL fibroblasts | - | higher cell growth, differentiation | | [184,186] |
| PLGA     | ACL fibroblasts | - | - | higher cell growth, differentiation | [186,188,189,194] |
| MSCs     | - | higher cell growth, differentiation | | [190,194] |
| TGF-β, GDF-5 | - | higher cell growth, differentiation | | [198] |
| PLGA     | MSCs | - | - | higher cell growth, differentiation | [196,197] |
| TGF-β, GDF-5 | - | higher cell growth, differentiation | | [198] |
| PGA      | - | FGF-2 | - | improved ACL repair (rats) | [203] |
| ACL fibroblasts | - | higher cell growth, differentiation | | [200,204–206] |
| MSCs     | - | higher cell growth, differentiation | | [201] |
| FGF-2    | + | higher cell growth, differentiation | | [199] |
| PU       | ACL fibroblasts | - | - | higher cell growth, differentiation | [168] |
| OPF      | MSCs | + | higher cell growth, differentiation | | [207] |
| PET      | ACL fibroblasts | - | - | higher cell growth, differentiation | [209] |
Table 1. Cont.

| Scaffolds          | Cells          | Factors | Bioreactors | Effects                                | Refs.     |
|--------------------|----------------|---------|-------------|----------------------------------------|-----------|
| collagen/GAG       | ACL explants   | -       | -           | higher cell migration, differentiation | [213,214] |
| collagen/silk      | -              | -       | -           | improved ACL repair (rabbits)          | [215–217] |
| collagen/p(DTD DD) | -              | -       | -           | improved ACL repair (sheep)            | [218]     |
| collagen/PRP       | -              | -       | -           | improved ACL repair (dogs, pigs)       | [164,225–228] |
| silk/PLGA          | MSCs           | FGF-2   | -           | higher cell growth, differentiation    | [219]     |
| chitosan/HA        | -              | -       | -           | improved ACL repair (rats)             | [220]     |
| chitosan/PLA       | ACL fibroblasts| -       | -           | higher cell growth, differentiation    | [221]     |
| chitosan/PCL       | ACL fibroblasts| -       | -           | higher cell growth, differentiation    | [222]     |
| PLA/PCL            | MSCs           | -       | -           | higher cell growth, differentiation    | [223]     |
| PGA/PCL            | ACL fibroblasts| -       | -           | higher cell growth, differentiation    | [184]     |
| PLA/PLGA           | MSCs           | -       | -           | improved ACL repair (rabbits)          | [224]     |

Abbreviations: HA, hyaluronic acid; PGA, poly(glycolic acid); PLA, poly(lactic acid); PLGA, poly(lactic-co-glycolic acid); PCL, poly(caprolactone); PU, polyurethane; OPF, oligo(poly(ethylene glycol) fumarate); PET, poly(ethylene terephthalate); GAG, glycosaminoglycan; p(DTD DD), poly(desaminotyrosyl-tyrosine dodecyl dodecanedioate); PRP, platelet-rich plasma; MSCs, bone marrow-derived mesenchymal stromal cells; ACL, anterior cruciate ligament; ASCs, adipose-derived MSCs; CTGF, connective tissue growth factor; TGF-β, transforming growth factor beta; FGF-2, basic fibroblast growth factor; PDGF, platelet-derived growth factor; EGF, epidermal growth factor; GDF-5, growth differentiation factor 5.

Such scaffolds have been further employed in conjunction with cells upon seeding onto biomaterials [2,42,43,45–47,49,54,56,59,60,62,64,67–70,213] such as differentiated fibroblasts and tissue (ACL, skin) [159,160,166,168,178,182,184,186,188,189,194,196,200,205,206,209,214,221,222] and progenitor cells (bone marrow-derived mesenchymal stromal cells—MSCs, adipose-derived MSCs—ASCs) [44,153,163,165,167,169–177,179,181,183,190,196–199,201,207,219,223,224], or even exosomes (extracellular vesicles carrying proteins, lipids, and nucleic acids and critical mediators of cell-cell communication) prepared from MSCs [230,231], tested in bioreactors to provide adaption to a dynamic environment with biomechanical cues to improve tissue repair [44,50,51,54,55,62,63,68,146,170,199,207] with further biological augmentation [8,45,47–49,54,56,60,65,68,70,155] including growth factors (TGF-β, basic FGF—FGF-2, growth differentiation factor 5—GDF-5, platelet-derived growth factor—PDGF, epidermal growth factor—EGF, connective tissue growth factor—CTGF, insulin) [151,154,172,198,199,203,219] and platelet-rich plasma (PRP, a derivative of whole blood with supraphysiological concentrations of platelets, with fibrin, and allowing for the release of growth factors and other bioactive substances and having inhibitory effects on inflammatory cytokines) [52,53,57–59,61,64–66,69–72,137,148,164,232–235] used as a hydrogel in combination with collagen [225–229] (Table 1).

While the use of biomaterial scaffolds with or without augmentation (cells, biological/mechanical stimuli) proved beneficial at least to a certain point experimentally, these
systems have again been unable to support long-lasting ACL repair, showing the critical need for improved treatment strategies to effectively manage this clinical problem. In this regard, gene therapy may provide powerful tools to adeptly heal sites of ACL injury.

3. Classical Gene Therapy for the Repair of ACL Injuries

Gene therapy is based on the transfer of genetic sequences in target cells, tissues/organs, and live organisms with gene vehicles as a means to prolong the therapeutic effects of one or various gene products relative to the application of recombinant factors with short half-lives [73–93,236,237]. Candidate factors for gene therapy may include growth and transcription factors, signaling molecules, as well as therapeutic RNAs that may be either suppressive (i.e., interfering) sequences such as oligodeoxyribonucleotide (ODNs), antisense RNAs, microRNAs (miRNAs), small interfering RNAs (siRNAs), short hairpin RNAs (shRNAs), and long non-coding RNAs (lncRNAs) or activating sequences such as messenger RNAs (mRNAs). Gene therapy can be performed either via a direct (in vivo) administration of the gene vector or via an indirect (ex vivo) supply of cells/grafts that are genetically modified in vitro prior to reimplantation in the recipient.

3.1. Gene Transfer Vectors

Gene vehicles include both nonviral and viral systems with specific characteristics that make them more adapted for in vivo or for ex vivo therapy (Table 2).

Table 2. Gene transfer vectors.

| Vectors | Integration | Advantages | Limitations |
|---------|-------------|------------|-------------|
| nonviral vectors | no | . large capacity . cost effectiveness . no infectiosity/replication . no toxicity/immunogenicity | low efficacy . short-term expression . only dividing cells |
| adenoviral | no | . large capacity . high efficacy | . short-term expression . toxicity/immunogenicity |
| HSV | no | . large capacity . high efficacy | . short-term expression . toxicity/immunogenicity |
| retroviral | yes | . large capacity . long-term expression | . low efficacy without selection . only dividing cells . toxicity/immunogenicity . potential insertional mutagenesis |
| lentiviral | yes | . large capacity . dividing/quiescent cells . long-term expression | . low efficacy without selection . toxicity/immunogenicity . potential insertional mutagenesis . HIV material |
| rAAV | no | . high efficacy . dividing/quiescent cells . long-term expression | . small capacity . possible immunogenicity . potential insertional mutagenesis |

Abbreviations: HSV, herpes simplex viral vector; rAAV, recombinant adeno-associated viral vectors; HIV, human immunodeficiency virus.

Nonviral vectors are non-replicative, non-immunogenic, safe systems without size limitation, but they exhibit a relatively low gene transfer efficiency for only very short periods of time (<40% for few weeks) since the genes being carried are kept as episomes that necessitate cell division for effective expression, making these vectors more suitable for ex vivo therapy [238,239].
Viral vectors that employ the ability of viruses to penetrate various cell types include adenoviral, herpes simplex viral (HSV), retro-l/lentiviral, and recombinant adeno-associated virus (rAAV) vectors. Adenoviral and HSV vectors are capable of directly modifying dividing and quiescent cells at elevated efficiencies (~100%), making them adapted for in vivo therapy, but they support only short-term (episomal) transgene expression (between some days to 1–2 weeks) while activating host immune responses [98,240–242]. Retroviral vectors have the ability to integrate in cellular genomes, allowing for long-term transgene expression, but they have low efficiencies (<20%), making them more suited for ex vivo therapy, and can only modify dividing cells, with possible insertional mutagenesis [243], while being also potentially immunogenic [98]. As an alternative, lentiviral vectors can also target quiescent cells, but they derive from the pathogenic human immunodeficiency virus (HIV) and may also lead to insertional mutagenesis [244]. rAAVs are small (~20 nm), safe vectors devoid of viral sequences and that are capable of modifying both dividing and quiescent cells at elevated efficiencies over extended periods of time (~100% for months to years) due to their maintenance as stably expressed episomes [245,246], making them adapted for in vivo therapy, but they may raise immune responses, in particular by pre-existing neutralizing antibodies directed against the viral capsid proteins [98,247–249].

3.2. Candidate Therapeutic Factors

Therapeutic factors amenable to gene transfer to repair ACL injuries include growth factors, transcription factors, anti-inflammatory agents, matrix components, and signaling molecules.

A variety of polypeptide growth factors have been reported for their beneficial activities to repair ACL injuries. They include TGF-β [198,250–258], bone morphogenetic proteins (BMPs) and GDFs (BMP-2; GDF-5, i.e., BMP-14; GDF-6, i.e., BMP-13; GDF-7, i.e., BMP-12) [198,259–262], FGF-2 [251,255,256,262–266], insulin-like growth factors (IGF-I, IGF-II) [250–252,266], PDGF [251,252,256,258,260,264,265,267,268], EGF [251,252,254,265,269,270], hepatocyte growth factor (HGF) [260], CTGF [151], and vascular endothelial growth factor (VEGF) [271,272]. These factors play critical roles in stimulating cellular activities relevant for ACL repair such as cell migration and proliferation (TGF-β, GDFs, BMP-2, FGF-2, IGF-I, PDGF, EGF, HGF, CTGF, VEGF) [151,198,251–253,255–258,260,262,263,265,267–270,272], cell adhesion (GDFs, FGF-2, EGF) [262,269], matrix deposition (type-I/-III collagen, proteoglycans) (TGF-β, GDFs, FGF-2, IGF-I/-II, PDGF, EGF, CTGF) [151,198,250,252,254–256,258,259,261,262,266,268], angiogenesis (FGF-2, PDGF, VEGF) [266,268,271,272], and mechanical properties (stiffness) (TGF-β, FGF-2, IGF-I, PDGF, VEGF) [151,257,258,264,268].

Transcription factors have been also described for their advantageous properties for ACL repair [115,118–120,273], among which are SCX, regulating cell differentiation and matrix synthesis (type-I collagen, fibromodulin, tenomodulin—TNMD, decorin), especially in tendon progenitors [113,114,117,274–279], and MKX, essential for tendon/ligament differentiation by regulating the expression of matrix components (type-I collagen, fibromodulin, TNMD, decorin, lumican) [116,280–283].

Other components may be used as potential candidates for the repair of ACL lesions such as factors that may prevent the potential inflammation associated with injury [284–295] such as an anti-inflammatory IL-1 receptor antagonist (IL-1Ra) [295–297], soluble TNF-α receptor [296], IL-10 [298,299], or lysyl oxidase (LOX), an enzyme that oxidizes amino acid residues in collagens and elastin, allowing these compounds to bind to each other and to repair the extracellular matrix, and which can suppress inflammation in ACL cells [300]. Alternative candidates for ACL repair may also conceptually include matrix components such as collagens [301,302], TNMD [303–306], decorin [307–309], fibromodulin [310], biglycan [308,309], or others, as their presence is critical to the natural structure and functional integrity of the ACL. Other factors may also tentatively provide interesting candidates for ACL repair, such as those involved in signaling processes involved in ACL formation (wingless integrated—Wnt-β-catenin, sonic hedgehog—SHH, FGF signaling via spe-
specific receptors, and ERK/MAPK, BMP/TGF-β/GDF signaling via specific receptors and Smads) [115,118,119,273,311,312].

3.3. Applications of Classical Gene Therapy for ACL Repair

Therapeutic gene therapy in the goal of ACL repair has been performed in relevant experimental models in cell culture in vitro, in tissue (explant) culture in situ, and in relevant animal models using both direct (in vivo) and indirect (ex vivo) gene transfer approaches.

In vitro and in situ (Table 3), the application of therapeutic genes has been reported using nonviral [313], adenoviral [282,314–324], retro-/lentiviral [275,283,314,315,325–327], and rAAV vectors [328].

Table 3. Applications of classical gene therapy for ACL repair in vitro and in situ.

| Vectors          | Cell Targets                          | Genes            | Effects                                                                 | Refs.         |
|------------------|---------------------------------------|------------------|------------------------------------------------------------------------|---------------|
| nonviral vectors | rabbit ligament cells                 | ODN (decorin)    | suppression of decorin expression (one day)                           | [329]         |
|                  | human tendon cells                    | ODN (TVPα1)      | suppression of TVPα1 expression (one day)                              | [330]         |
|                  | horse, bovine, sheep, pig, rat tendons| mRNA (lacZ, luc, BMP-7) | effective gene expression (one day)                                 | [331]         |
|                  | rabbit perichondrial cells            | lacZ, TGF-β      | effective gene expression (2 days)                                     | [313]         |
|                  | rabbit ACL cells                      | lacZ, TGF-β, VEGF| effective gene expression, high DNA, type-I/-III collagen, FN contents (3 days) | [314,315,320] |
|                  | bovine ACL cells                      | GFP, luc, TGF-β (type-I collagen gel) | effective gene expression (6 days), high DNA and type-I/-III collagen contents (3 weeks) | [317]         |
|                  | human ACL cells                       | GFP, luc, BMP-12, -13, IGF-I (type-I collagen gel) | effective gene expression, high DNA, type-I/-III collagen, tenasin, TNMD, elastin, vimentin, decorin, FN, biglycan, SCX contents (3 weeks) | [318,322]     |
|                  | murine MSC line                       | BMP-12           | effective gene expression (5 days)                                     | [316,332]     |
|                  | rat MSCs                              | SCX              | effective gene expression (one day)                                    | [323]         |
|                  | rabbit MSCs                           | TGF-β, VEGF      | effective gene expression (2 days)                                     | [321]         |
|                  | human MSCs                            | BMP-12, -13 (type-I collagen gel) | effective gene expression (2 weeks), high DNA, type-III collagen, tenasin, TNMD, elastin, vimentin, decorin, FN, biglycan, SCX contents (3 weeks) | [322,324]     |
|                  |                                        | SCX, MKX         | effective gene expression, high type-I collagen, tenasin, TNMD contents (one week) | [282]         |
Table 3. Cont.

| Vectors       | Cell Targets          | Genes               | Effects                                           | Refs.             |
|---------------|-----------------------|---------------------|--------------------------------------------------|-------------------|
| retroviral vectors | rabbit ACL cells     | *lacZ*              | effective gene expression (one week)             | [314,315]         |
|               | murine MSC line       | MKX                 | high type-I collagen, decorin contents (5 days)  | [283]             |
|               | rabbit MSCs           | PDGF                | effective gene expression (12 weeks)             | [333]             |
|               | human tendon-derived stem cells | lncRNA (H19)       | enhanced tenogenic differentiation (one week)    | [334]             |
|               | rat tendon cells      | shRNA (decorin)     | suppression of decorin expression (3 days)       | [335]             |
|               | rat ACL-derived stem cells | VEGF              | effective gene expression (2 days)               | [325]             |
|               | rat tendon-derived stem cells | miRNA (ROCK1)    | high tenogenic differentiation (one week)        | [336]             |
|               | human MSCs            | SCX                 | effective gene expression, high type-I collagen, TNMD, decorin, FN, fibromodulin, lumican, α-SMA contents (cell selection) | [275]             |
|               | human ACL-derived stem cells | BMP-2              | effective gene expression (3 days)               | [326]             |
|               | human iPSCs           | MKX                 | high type-III collagen, decorin, fibromodulin, SCX contents (cell selection) | [327]             |
| lentiviral vectors | human ACL cells, explants (normal, torn) | *lacZ*, FGF-2   | effective gene expression, high DNA, type-I/-III collagen, SCX, α-SMA, NF-κB contents (one month) | [328]             |

Abbreviations: rAAV, recombinant adeno-associated viral vectors; ACL, anterior cruciate ligament; MSCs, mesenchymal stromal cells; iPSCs, induced pluripotent stem cells; ODN, oligodeoxyribonucleotide; TVPα1, type V procollagen α1 chain; mRNA, messenger ribonucleic acid; *lacZ*, β-galactosidase; *luc*, luciferase; BMP, bone morphogenetic protein; TGF-β, transforming growth factor beta; VEGF, vascular endothelial growth factor; GFP, green fluorescent protein; IGF-I, insulin-like growth factor I; SCX, scleraxis; MKX, Mohawk; PDGF, platelet-derived growth factor; lncRNA, long non-coding RNA (H19 involved in TGF-β signaling); shRNA, short hairpin RNA; miRNA, microRNA; ROCK1, Rho-associated coiled-coil protein kinase 1; FGF-2, basic fibroblast growth factor; DNA, deoxyribonucleic acid; TNMD, tenomodulin; FN, fibronectin; α-SMA, alpha-smooth muscle actin; NF-κB, nuclear factor kappa B.

These vectors were employed to deliver reporter genes (β-galactosidase—*lacZ*, green fluorescent protein—GFP, luciferase—*luc*) [313–315,317,318,328] and therapeutic sequences (TGF-β, BMP-2, BMP-12, BMP-13, FGF-2, IGF-I, PDGF, VEGF, SCX, MKX) [275,282,283,313,316–327,333] in rabbit, bovine, and human ACL cells and ACL explant (normal, experimentally torn) tissue [314,315,317,318,320,322,328] and in mouse, rat, rabbit, and human progenitor cells (MSCs, ACL-derived stem cells, perichondrial cells, induced pluripotent stem cells—iPSCs) [275,282,283,313,316,319,321–327,333]. Gene transfer allowed for an effective expression of the sequences being delivered for up to 2 days using nonviral vectors [313], one week using adenoviral vectors [282,314–321,323] or longer (2 weeks) if the modified cells where placed in hydrogel (type-I collagen) cultures [322], 12 weeks using retro-/lentiviral vectors upon cell selection [283,314,315,319,325–327,333], and at least one month using rAAV vectors [328]. Therapeutic gene transfer (TGF-β, BMP-12, BMP-13, FGF-2, IGF-I, VEGF) was capable of enhancing cell proliferation [317,318,320,322,328] using adenoviral vectors [317,318,320,322] for up to 2 weeks [317] and rAAV vectors for up to one month [328]. Therapeutic gene transfer (TGF-β, BMP-12, BMP-13, FGF-2, IGF-I, VEGF, SCX, MKX) also led to increased levels of matrix deposition and of specific marker expression (type-I/-III collagen, elastin, vimentin, fibromodulin,
fibronectin—FN, tenascin, TNMD, decorin, lumican, biglycan, SCX, contractile alpha-smooth muscle actin—α-SMA) [275,282,283,317,318,320,322,324,327,328] using adenoviral vectors [282,317,318,320,324] for up to 3 weeks [283,317,322], retro-/lentiviral vectors over time upon cell selection [275,283,327], and rAAV vectors for up to one month [282]. Strikingly, rAAV-mediated gene delivery of FGF-2 over time (one month) was able to heal experimentally created human ACL lesions in situ via the enhanced expression of contractile α-SMA and of the ligament-specific SCX transcription factor and via increased collagen deposition [328]. Therapeutic RNAs have been also applied in vitro [329,330,334–336] and in situ [331], based on the delivery of ODNs (decorin, type V procollagen α1 chain) [329], miRNAs (Rho-associated coiled-coil protein kinase 1—ROCK1) [336], shRNAs (decorin) [335], lncRNAs (H19 lncRNA involved in TGF-β signaling) [334], and mRNAs (BMP-7) [331] using nonviral [329–331] and retro-/lentiviral vectors [334–336] to target rat, rabbit, and human ACL (and tendon) cells and explant tissue [329–331] and rat and human progenitor cells (tendon-derived stem cells) [334,336], allowing to suppress the expression of each specific marker while improving the ligamentous/tenogenic phenotype for up to one week [329–331,334–336].

Direct (in vivo) administration of therapeutic genes in animal models (Table 4) has been performed using nonviral [337–339] and adenoviral vectors [340–342] to deliver reporter genes (lacZ) [337,339–341] and therapeutic sequences (BMP-13, PDGF) [338,342] in experimentally created ligamentous lesions in rats [337–339,342] and in rabbits [340,341], allowing for the effective expression of the sequences being delivered for up to 2 weeks using nonviral vectors [337,339] and 6 weeks using adenoviral vectors at very high doses [340].

Therapeutic gene transfer (BMP-13, PDGF) was capable of enhancing type-I collagen deposition for 4 weeks in injured rat ligaments using nonviral vectors (PDGF) [338] and of promoting neoligament formation with increased levels of cell proliferation and collagen deposition for up to 14 weeks in a similar experimental model using adenoviral vectors (BMP-13) [342]. Therapeutic RNAs have been also directly applied in vivo [331,343–345], based on the delivery of ODNs (decorin) [343,345] and mRNAs (BMP-7, FGF-2) [331,344] using nonviral vectors [331,343,345] or only RNA solutions [344] in experimentally created ligamentous lesions in vivo in rats [331,344], in rabbits [343,345], and in sheep [331], allowing to suppress the expression of each specific marker while enhancing collagen deposition, mechanical stiffness, and healing for up to 6 weeks [331,343–345].

Indirect (ex vivo) application of therapeutic genes in animal models (Table 5) has been performed using nonviral [346], adenoviral [316,341,347,348], and retro-/lentiviral vectors...
Vectors [325,326,333,340] to deliver reporter genes (lacZ, GFP) [340,341,346,347] and therapeutic sequences (TGF-β, BMP-2, BMP-6, BMP-12, PDGF, VEGF) [316,325,333,346–348] as a means to modify rabbit ACL cells [340,341], rabbit and minipig ACL and tendon tissue grafts [346,347], and mouse, rat, rabbit, and human progenitor cells (MSCs, ACL-derived stem cells) [316,325,332,333,348] prior to applying them to ectopic models (muscle injection) in mice [316] or to experimentally created ligamentous lesions or for ACL replacement and repair in vivo [325,326], in rabbits [333,340,341,347,348], and in minipigs [346], allowing for the effective expression of the sequences being delivered for up to 2 weeks using nonviral vectors [346] or adenoviral vectors [341,347] and 10 days using retro-/lentiviral vectors [340].

| Vectors      | Animal Models          | Cells                  | Genes         | Effects                                                                 | Refs. |
|--------------|------------------------|------------------------|---------------|-------------------------------------------------------------------------|-------|
| nonviral     | minipig ACL lesion     | ACL graft              | GFP, BMP-6    | effective gene expression (2 weeks), ACL repair with stronger mechanical properties (8 weeks) | [346] |
| adenoviral   | mouse ectopic injection (muscle) | murine MSC line | BMP-12       | high collagen deposition, neoligament formation (4 weeks)               | [316] |
| retroviral   | rabbit ligament lesion | rabbit ACL cells       | lacZ          | effective gene expression (2 weeks)                                     | [341] |
|              | rabbit ACL lesion      | rabbit MSCs            | TGF-β, VEGF   | ACL remodeling with stronger mechanical properties (24 weeks)          | [348] |
|              | rabbit tendon graft    | rabbit MSCs            | PDGF          | high collagen deposition, ligament remodeling (10 days)                | [333] |
| lentiviral   | mouse tendon injury    | human tendon-derived stem cells | lncRNA (H19) | high type-I collagen deposition, TNMD, decorin contents (4 weeks)     | [334] |
| rat ACL lesion | rat ACL-derived stem cells | BMP-2 | high type-I/III collagen deposition, α-SMA contents, ACL repair (8 weeks) | [326] |
| rat tendon injury | rat ACL-derived stem cells | VEGF | high type-I collagen deposition, ligament remodeling with stronger mechanical properties (4 weeks) | [325] |
|              | rat tendon cells       | shRNA (decorin)        | high collagen deposition (4 weeks)                                   | [335] |

Table 5. Applications of classical gene therapy for indirect ACL repair ex vivo.

---

Therapeutic gene transfer (TGF-β, BMP-2, BMP-6, BMP-12, PDGF, VEGF) was capable of enhancing matrix deposition and specific marker expression (type-I/III collagen, α-SMA) and promoting neoligament formation with increased levels of collagen deposition.
and improved mechanical properties in injured mouse, rat, rabbit, and minipig ligaments for up to 8 weeks using nonviral vectors (BMP-6) [346], 26 weeks using adenoviral vectors (TGF-β, BMP-2, BMP-12, VEGF) [316,347,348], and 12 weeks using retro-/lentiviral vectors (BMP-2, PDGF, VEGF) [325,326,333]. Therapeutic RNAs have been also indirectly applied in vivo [334,335], based on the delivery of shRNAs (decorin) [335] and IncRNAs (H19 IncRNA involved in TGF-β signaling) [334] using retro-/lentiviral vectors [334,335] as a means to modify rat tendon cells [335] and human progenitor cells (tendon-derived stem cells) [334] prior to applying them to experimentally created tendon lesions in vivo in mice [334] and in rats [335], allowing to enhance matrix deposition and specific marker expression (type-I collagen, TNMD, decorin) for up to 4 weeks [334,335].

3.4. Limitations of Classical Gene Therapy for ACL Repair

While experimental work showed the potential benefits of classical gene therapy for ACL repair, a number of critical limitations need to be carefully addressed before initiating relevant approaches for translational regenerative therapy in the field of clinically adapted repair in patients.

ACL gene therapy may be first hindered by pre-existing physical obstacles and biological barriers to effective and safe therapeutic gene transfer, including the presence of inhibitory factors in the joint (body fluids, i.e., synovial fluid; clinical compounds, i.e., heparin), the local pH and/or enzymatic environment, and the dense extracellular matrix of the tissue itself that may impair the penetration of the vectors before reaching the target cells [82,83,85,87,90,349]. Another impairment is associated with the existence of innate and/or adaptive responses from the immune system of the recipient (antibodies, cellular helper, and cytotoxic T cells) that may be directed against the viral particles and/or the transgene sequence (neutralization processes) [98,247,350–353]. Various cell-associated steps may also limit the rate and occurrence of therapeutic gene expression such as the effective uptake of the gene vector (presence/amount of the specific cell membrane receptor/co-receptor to a particular vector type), its successful internalization and transport in the cell (endosomal escape and nuclear entry), as well as its active processing (levels of adapted cell activity, transgenic genome conversion) [94–96,241,354–356]. Other challenges to address also involve inherent features of the vectors that may potentially affect the efficacy of the therapeutic treatment (vector dissemination to non-target sites in the joint, toxicity of viral vector proteins, genotoxicity upon a possible transgene integration in the host genome, transformation risk) [97].

A variety of strategies have been developed to tackle such issues, including (1) the use of alternative routes of vector injection, vector doses, clinical components (passive hirudin versus inhibitory heparin), immunosuppressive agents, and/or alternative (viral) vector serotypes, (2) the modification/masking of viral particles to evade host immune responses (chemical conjugation with polyethylene glycol—PEG, tropism/viral capsid tailoring by inclusion of substitute peptide sequences/epitopes, viral capsid engineering using chimeric/hybrid/mosaic/shuffled/variant/mutant/decoy vectors or virus-like particles—VLPs, vector-like microvesicles, vexosomes), and (3) the modification of the vector genome to circumvent the rate-limiting steps of its intracellular processing (tissue-specific/activatable/disease-responsive promoters, hybrid/self-complementary vectors, optimized coding/noncoding sequences in the transgene cassettes, artificial chromosomes) [82,83,85,87,90,96,245,357–361]. Still, even though such approaches led to some improvements in the efficacy of gene transfer, they remain complex (capsid/vector genome modification and engineering) or do not allow for sufficient and adapted therapeutic effects and outcomes, especially in vivo, while the variability of the host immune responses between patients has not been carefully taken into account with any of these techniques. Overall, these observations show the critical need to develop novel, suitable tools to address such challenges for clinical gene therapy, in particular for human ACL repair.
4. Biomaterial-Guided Gene Therapy for the Repair of ACL Injuries

The administration of therapeutic gene vectors using biomaterials already employed in tissue engineering research is an attractive approach to tackle the current obstacles of clinical human gene therapy and regenerative medicine [82, 83, 85–87, 90, 93, 102–104, 362, 363] and might be applied in the goal of human ACL repair [90, 91].

4.1. Principles

Biomaterial-guided gene therapy is a groundbreaking, convenient therapeutic concept based on the controlled delivery of gene transfer vectors from biocompatible scaffolds (hydrogels, solid scaffolds) originating from approaches developed to apply drugs and recombinant agents with such systems in human medicine [139, 364–369]. Biomaterial-guided gene therapy instead combines the application of gene vehicles using materials (cargos) that may mimic the properties of the ACL tissue while strengthening it [99–101, 370–382] in order to allow for a spatiotemporal, safe expression of therapeutic genetic sequences in the recipient via an off-the-shelf, cell-free (patient-independent) compound. Biomaterials may be derived from natural (biocompatible, biodegradable) or synthetic (reproducible) components, or both, to either encapsulate gene vectors to achieve a polymeric vector release (gradient release by degradation of the polymer loaded with the vectors during scaffold formation for hydrogels) or to immobilize the gene vectors to achieve a substrate-mediated release (release of the vectors incorporated at the surface of preformed scaffolds for solid scaffolds) [383]. Gene therapy guided via controlled release from biomaterials may allow for the stabilization of the gene vectors against degradation, to enhance the residence time of the therapeutic genes being carried and the effects of their products, to minimize vector dissemination to nontarget sites and the vector doses needed to be applied in patients, and to mask potentially immunogenic viral particle epitopes and protect the vectors from host immune responses [82, 83, 85, 87, 90, 102].

4.2. Applications of Biomaterial-Guided Gene Therapy for ACL Repair

In vitro and in situ (Table 6), biomaterial-guided application of therapeutic genes has been reported using nonviral [384] and adenoviral vectors [317, 318] delivered via type-I collagen hydrogels [317, 318] and PLGA nanospheres [384]. These vectors were employed to transfer reporter genes (GFP) [317, 318, 384] and therapeutic sequences (TGF-β, IGF-I) [317, 318] in bovine ACL cells [317], chicken tendon cells [384], and bovine and human ACL explant (experimentally torn) tissue [317, 318].

Table 6. Applications of biomaterial-guided gene therapy for ACL repair.

| Animal Models | Vectors | Cell Targets | Genes | Biomaterials | Effects | Refs. |
|---------------|---------|--------------|-------|--------------|---------|-------|
| nonviral vectors | chicken tendon cells | GFP, miRNA (TGF-β) | PLGA nanospheres | effective gene expression (GFP), suppression of TGF-β expression (miRNA TGF-β) (3 weeks) | [384] |
| adenoviral vectors | bovine ACL cells | GFP | type-I collagen gel | effective gene expression (3 weeks) | [317] |
| | bovine ACL explants (torn) | TGF-β | type-I collagen gel | effective gene expression, high type-I/-III deposition, ACL repair (4 weeks) | [317] |
| | human ACL explants (torn) | GFP, IGF-I | type-I collagen gel | effective gene expression, high DNA contents (IGF-I) (3 weeks) | [318] |
| Animal Models                  | Vectors        | Cell Targets | Genes   | Biomaterials                  | Effects                                                                 | Refs.                  |
|-------------------------------|----------------|--------------|---------|-------------------------------|------------------------------------------------------------------------|------------------------|
| rabbit ACL lesion             | nonviral vectors| -            | TGF-β   | tendon graft                  | high collagen deposition, wound healing with stronger mechanical properties (6 months) | [385]                  |
| chicken tendon injury         | nonviral vectors| -            | miRNA (TGF-β) | PLGA nanospheres, 3DB composite (PCL, PDA NPs, gelatin, HA, alginate) | suppression of TGF-β expression, wound healing (6 weeks) | [384,386]             |
| rat tendon injury             | adenoviral vectors | -            | BMP-12 | muscle graft                  | high collagen deposition, wound healing (4 weeks) | [319]                  |
|                               | lentiviral vectors | -            | shRNA (decorin) | tendon graft                  | high collagen deposition, wound healing (4 weeks) | [335]                  |
| mouse tendon injury           | rAAV vectors   | -            | luc, GDF-5 | tendon graft                  | effective gene expression, wound healing with stronger mechanical properties (2–3 weeks) | [387,388]             |
| rat ACL lesion, tendon injury | -              | -            | miRNA (angiogenic miR-210) | type-I collagen gel | high type-I collagen deposition, VEGF expression, wound healing with stronger mechanical properties (4–12 weeks) | [389–391]             |

Abbreviations: ACL, anterior cruciate ligament; rAAV, recombinant adeno-associated viral vectors; GFP, green fluorescent protein; miRNA, microRNA; TGF-β, transforming growth factor beta; IGF-I, insulin-like growth factor I; BMP-12, bone morphogenetic protein 12; shRNA, short hairpin RNA; GDF-5, growth differentiation factor 5; luc, luciferase; PLGA, polylactic-co-glycolic acid; PCL, polycaprolactone; PDA NPs, polydopamine nanoparticles; HA, hyaluronic acid; VEGF, vascular endothelial growth factor.

Gene transfer allowed for an effective expression of the sequences being delivered for up to 3 weeks using nonviral vectors [384] and 4 weeks using adenoviral vectors [317,318]. Therapeutic gene transfer (TGF-β, IGF-I) was capable of enhancing cell proliferation using adenoviral vectors for up to 3 weeks [318] and the levels of matrix deposition (type-I/-III collagen) using adenoviral vectors for up to 4 weeks [317]. Strikingly, adenoviral-mediated gene delivery of TGF-β was further able to heal experimentally created bovine ACL lesions over a prolonged period of time (4 weeks) in situ [317]. Therapeutic RNAs have been also applied in vitro (Table 6) via delivery of miRNAs (TGF-β) using nonviral vectors delivered via PLGA nanospheres to target chicken tendon cells, allowing for the suppression of the expression of TGF-β for up to 3 weeks [384].

Biomaterial-guided application of therapeutic genes in animal models (Table 6) has been performed using nonviral [385], adenoviral [319], and rAAV vectors [387,388] to deliver reporter genes (luc) [388] and therapeutic sequences (TGF-β, GDF-5, BMP-12) [319,385,387,388] as a means to modify mouse [387,388] and rabbit tendon tissue grafts [385] and rat muscle tissue grafts [319] prior to applying them to experimentally created tendon and ligamentous lesions for tissue replacement and repair in vivo in mice [387,388], in rats [319], and in rabbits [385], allowing for the effective expression of the sequences being delivered for up to 3 weeks [387]. Therapeutic gene transfer (TGF-β, GDF-5, BMP-12) was capable of promoting wound healing with increased levels of collagen deposition and improved mechanical properties in injured mouse, rat, and rabbit tendons and ligaments for up to 6 months using nonviral vectors (TGF-β) [385], 4 weeks using adenoviral vectors (BMP-12) [319], and 3 weeks using rAAV vectors (GDF-5) [387,388]. Therapeutic RNAs have been...
also applied via biomaterials in animal models (Table 6) [335,384,386,389–391], based on the delivery of shRNAs (decorin) [335] and miRNAs (TGF-β, angiogenic miR-210) [384,386,389–391] using nonviral [384,386] and lentiviral vectors [335] or only as RNA solutions [389–391] delivered via rat tendon tissue grafts [335], type-I collagen hydrogels [389–391], PLGA nanospheres [384], and 3D-bioprinted composite (PCL, polydopamine—PDA—nanoparticles—NPs, gelatin, HA, alginate) scaffolds [386] in experimentally created tendon and ligamentous lesions for tissue replacement and repair in vivo in rats [335,389–391] and in chickens [384,386], allowing to suppress the expression of the specific marker (TGF-β) for up to 6 weeks [384] while enhancing matrix deposition and specific marker expression (type-I collagen, VEGF), mechanical stiffness, and healing for up to 12 weeks [335,384,386,389–391].

5. Conclusions

To address the unsolved problem of achieving long-lasting, safe, and mechanically competent ACL repair in patients, as none of the currently available clinical options (ACL reconstruction, engineering, augmentation) can competently afford it thus far, advanced strategies were developed to improve the intrinsic mechanisms of tissue repair in prevalent ACL injuries based on gene therapy procedures using durable therapeutic gene transfer (growth/transcription factors, anti-inflammatory agents, matrix components, signaling molecules, therapeutic RNAs) in vectors in experimental systems in vitro and in situ and relevant animal models in vivo via classical gene transfer methods (direct gene vector administration, indirect implantation of genetically modified cells and tissues). While such experimental approaches met undeniable success, they may be limited by the existence of physical and biological barriers in patients such as the joint environment (inhibitory soluble factors, dense extracellular matrix, immune host responses) and rate-limiting steps to effective therapeutic gene expression (ACL cell-associated rate-limiting steps, vector dissemination and toxicity). Besides active work using complex vector engineering techniques, a more convenient strategy, namely biomaterial-guided gene therapy, has emerged to tackle these issues via the application of biocompatible materials as cargos for therapeutic gene vectors, allowing for their spatiotemporal, safe, and prolonged controlled release and expression in the recipient while mimicking the properties of the ACL tissue and strengthening it. With promising results reported in experimental systems in vitro and in situ and in relevant animal models in vivo using this highly innovative procedure, work is now needed to confirm its workability in large preclinical animal models before envisaging a possible translation in individuals that first requires approval by regulatory organizations [83,392–394]. With this in mind, it still remains to be determined which biomaterial (type, production method possibly including three-dimensional—3D—bioprinting to mimic the structural features of the ACL) [395–399], vector (class, dose), and gene (single sequence or combination of genes, potential use of direct genome editing such as the clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated (Cas) system) [400–409] will be the most appropriate to effectively and permanently heal ACL lesions in order to be accessible to the patients in a near future.

Author Contributions: Conceptualization, M.A., V.M. and M.C.; writing—original draft preparation, M.A. and M.C.; writing—review and editing, M.A., J.K.V., W.L., A.L., T.N.N., H.M., V.M. and M.C.; supervision, M.C.; funding acquisition, V.M., H.M. and M.C. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the World Arthrosis Foundation (M.C. and H.M.) and as part of the “Future Investment Project” by the French Public Investment Bank and the French state—PSPC application—Liga2bio project (V.M.). We acknowledge support by the Saarland University within the funding program Open Access Publishing.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.
Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

References

1. Kaeding, C.C.; Léger-St-Jean, B.; Magnussen, R.A. Epidemiology and Diagnosis of Anterior Cruciate Ligament Injuries. *Clin. Sport. Med.* 2016, 36, 1–8. [CrossRef] [PubMed]

2. Kiapour, A.M.; Murray, M.M. Basic science of anterior cruciate ligament injury and repair. *Bone Jt. Res.* 2014, 3, 20–31. [CrossRef] [PubMed]

3. Prodromos, C.C.; Han, Y.; Rogowsky, J.; Joyce, B.; Shi, K. A Meta-analysis of the Incidence of Anterior Cruciate Ligament Tears as a Function of Gender, Sport, and a Knee Injury–Reduction Regimen. *Arthrosco. J. Arthrosco. Relat. Surg.* 2007, 23, 1320–1325.e6. [CrossRef] [PubMed]

4. Fetko, J.F.; Marshall, J.L. The natural history and diagnosis of anterior cruciate ligament insufficiency. *Clin. Orthop. Relat. Res.* 1980, 147, 29–38. [CrossRef]

5. Murray, M.M.; Martin, S.D.; Martin, T.L.; Spector, M. Histological Changes in the Human Anterior Cruciate Ligament after Rupture. *J. Bone Jt. Surg.* 2000, 82, 1387–1397. [CrossRef]

6. Woo, S.L.-Y.; Vogrin, T.M.; Abramowitch, S.D. Healing and Repair of Ligament Injuries in the Knee. *J. Am. Acad. Orthop. Surg.* 2000, 8, 364–372. [CrossRef]

7. Duthon, V.L.A.; Barea, C.; Abrassart, S.; Fasel, J.H.; Fritschy, D.; Menetrey, J. Anatomy of the anterior cruciate ligament. *Knee Surg. Sport. Traumatol. Arthrosc.* 2006, 14, 204–213. [CrossRef]

8. Murray, M.M. Current Status and Potential of Primary ACL Repair. *Clin. Sport. Med.* 2009, 28, 51–61. [CrossRef]

9. Jung, H.-J.; Fisher, M.B.; Woo, S.L.-Y. Role of biomechanics in the understanding of normal, injured, and healing ligaments and tendons. *BMC Sport. Sci. Med. Rehabil.* 2009, 1, 9–17. [CrossRef]

10. Murray, M.M.; Fleming, B.C. Biology of anterior cruciate ligament injury and repair: Kappa delta ann donor vaughn award paper 2013. *J. Orthop. Res.* 2013, 31, 1501–1506. [CrossRef]

11. Yang, G.; Rothrauff, B.B.; Tuan, R.S. Tendon and ligament regeneration and repair: Clinical relevance and developmental paradigm. *Birth Defects Res. Part C Embryo Today Rev.* 2013, 99, 203–222. [CrossRef]

12. Kannus, P.; Jarvinen, M. Nonoperative treatment of acute knee ligament injuries. A review with special reference to indications and methods. *Sports Med.* 1990, 9, 244–260. [CrossRef]

13. Jokl, P.; Kaplan, N.; Stovell, P.; Keggi, K. Non-operative treatment of severe injuries to the medial and anterior cruciate ligaments of the knee. *J. Bone Jt. Surg.* 1984, 66, 741–744. [CrossRef]

14. Buss, D.D.; Min, R.; Skyhar, M.; Galinat, B.; Warren, R.F.; Wickiewicz, T.L. Nonoperative Treatment of Acute Anterior Cruciate Ligament Injuries in a Selected Group of Patients. *Am. J. Sport. Med.* 1995, 23, 160–165. [CrossRef]

15. Ciccotti, M.G.; Lombardo, S.J.; Nonweiler, B.; Pink, M. Non-operative treatment of ruptures of the anterior cruciate ligament in middle-aged patients. Results after long-term follow-up. *J. Bone Jt. Surg.* 1994, 76, 1315–1321. [CrossRef]

16. Maffulli, N. Rehabilitation of an anterior cruciate ligament. *Clin. Orthop. Relat. Res.* 1997, 343, 253–255. [CrossRef]

17. Frank, C.B.; Jackson, D.W. Current Concepts Review—The Science of Reconstruction of the Anterior Cruciate Ligament. *J. Bone Jt. Surg.* 1997, 79, 1556–1576. [CrossRef]

18. Fu, F.H.; Bennett, C.H.; Luterman, C.; Ma, C.B. Current trends in anterior cruciate ligament reconstruction. Part I. Biology and biomechanics of reconstruction. *Am. J. Sport. Med.* 1999, 27, 821–830. [CrossRef]

19. Fu, F.H.; Bennett, C.H.; Ma, C.B.; Menetrey, J.; Luterman, C. Current trends in anterior cruciate ligament reconstruction. Part II. Operative procedures and clinical correlations. *Am. J. Sport. Med.* 2000, 28, 124–130. [CrossRef]

20. Andersson, C.; Odensten, M.; Gillquist, J. Knee function after surgical or nonsurgical treatment of acute rupture of the anterior cruciate ligament: A randomized study with a long-term follow-up period. *Clin. Orthop. Relat. Res.* 1991, 264, 255–263. [CrossRef]

21. Delincé, P.; Ghafli, D. Anterior cruciate ligament tears: Conservative or surgical treatment? A critical review of the literature. *Knee Surg. Sport. Traumatol. Arthrosc.* 2012, 20, 48–61. [CrossRef] [PubMed]

22. Paschos, N.K.; Howell, S.M. Anterior cruciate ligament reconstruction: Principles of treatment. *EFORT Open Rev.* 2016, 1, 398–408. [CrossRef] [PubMed]

23. Noyes, F.R.; Butler, D.L.; Grood, E.S.; Zernicke, R.F.; Helfzby, M.S. Biomechanical analysis of human ligament grafts used in knee-ligament repairs and reconstructions. *J. Bone Jt. Surg.* 1984, 66, 344–352. [CrossRef]

24. Silver, F.H.; Tria, A.J.; Zawadsky, J.P.; Dunn, M. Anterior cruciate ligament replacement: A review. *J. Long-Term Eff. Med. Implant.* 1991, 1, 135–154. [CrossRef]

25. Chang, S.K.; Egami, D.K.; Shaieb, M.D.; Kan, D.M.; Richardson, A.B. Anterior cruciate ligament reconstruction: Allograft versus autograft. *Arthrosco. J. Arthrosco. Relat. Surg.* 2003, 19, 453–462. [CrossRef]

26. Mascarenhas, R.; MacDonald, P.B. Anterior cruciate ligament reconstruction: A look at prosthetics—past, present and possible future. *Mcgill. J. Med.* 2008, 11, 29–37. [CrossRef]
27. Chen, J.; Xu, J.; Wang, A.; Zheng, M. Scaffolds for tendon and ligament repair: Review of the efficacy of commercial products. Expert Rev. Med. Devices 2009, 6, 61–73. [CrossRef]
28. Legnani, C.; Ventura, A.; Terzaghi, C.; Borgo, E.; Alibisetti, W. Anterior cruciate ligament reconstruction with synthetic grafts. A review of literature. Int. Orthop. 2010, 34, 465–471. [CrossRef]
29. Vunjak-Novakovic, G.; Altman, G.; Horan, R.; Kaplan, D.L. Tissue Engineering of Ligaments.
30. Ritchie, J.R.; Parker, R.D. Graft Selection in Anterior Cruciate Ligament Revision Surgery. Clin. Orthop. Relat. Res. 1996, 325, 65–77. [CrossRef]
31. Aglietti, P.; Buzzi, R.; Giron, F.; Simeone, A.J.V.; Zaccherotti, G. Arthroscopic-assisted anterior cruciate ligament reconstruction with the central third patellar tendon. Knee Surg. Sport. Traumatol. Arthrosc. 1997, 5, 138–144. [CrossRef]
32. Bach, B.R.; Tradonsky, S.; Bochuk, J.; Levy, M.E.; Bush-Joseph, C.A.; Khan, N.H. Arthroscopically Assisted Anterior Cruciate Ligament Reconstruction Using Patellar Tendon Autograft. Am. J. Sports Med. 1998, 26, 20–29. [CrossRef]
33. Legnani, C.; Ventura, A.; Terzaghi, C.; Borgo, E.; Alibisetti, W. Anterior cruciate ligament reconstruction with synthetic grafts. A review of literature. Int. Orthop. 2010, 34, 465–471. [CrossRef]
34. Kahn, C.J.; Vaquette, C.; Rahouadj, R.; Wang, X. A novel bioreactor for ligament tissue engineering. Tissue Eng. Part B 2006, 12, 269–273. [CrossRef]
35. Angel, M.J.; Sgaglione, N.A.; Grande, D.A. Clinical applications of bioactive factors in sports medicine: Current concepts and future trends. Sports Med. Arthrosc. Rev. 2006, 14, 138–145. [CrossRef] [PubMed]
36. Petrigliano, F.A.; McAllister, D.R.; Wu, B.M. Tissue Engineering for Anterior Cruciate Ligament Reconstruction: A Review of Current Strategies. Arthrosc. J. Arthrosc. Relat. Surg. 2006, 22, 441–451. [PubMed]
37. Angel, M.J.; Sgaglione, N.A.; Grande, D.A. Clinical applications of bioactive factors in sports medicine: Current concepts and future trends. Sports Med. Arthrosc. Rev. 2006, 14, 138–145. [CrossRef] [PubMed]
38. Angel, M.J.; Sgaglione, N.A.; Grande, D.A. Clinical applications of bioactive factors in sports medicine: Current concepts and future trends. Sports Med. Arthrosc. Rev. 2006, 14, 138–145. [CrossRef] [PubMed]
39. Woo, S.L.Y.; Fisher, M.B.; Feola, A. Contribution of biomechanics to management of ligament and tendon injuries. Mol. Cell Biomech. 2008, 5, 49–68. [PubMed]
40. Kahn, C.J.; Vaquette, C.; Rahouadj, R.; Wang, X. A novel bioreactor for ligament tissue engineering. Biomed. Mater. Eng. 2008, 18, 283–287. [CrossRef] [PubMed]
41. Benhard, H.A.; Cosgroff-Hernandez, E.M. The Role of Mechanical Loading in Ligament Tissue Engineering. Tissue Eng. Part B Rev. 2009, 15, 467–475. [CrossRef] [PubMed]
42. Hall, M.P.; Band, P.A.; Meislin, R.J.; Jazrawi, L.M.; Cardone, D.A. Platelet-rich Plasma: Current Concepts and Application in Sports Medicine. J. Am. Acad. Orthop. Surg. 2009, 17, 602–608. [CrossRef]
43. Taylor, D.W.; Petera, M.; Hendry, M.; Theodoropoulos, J. A Systematic Review of the Use of Platelet-Rich Plasma in Sports Medicine as a New Treatment for Tendon and Ligament Injuries. Clin. J. Sport Med. 2011, 21, 344–352. [CrossRef]
44. Rodrigues, M.T.; Reis, R.L.; Gomes, M.E. Engineering tendon and ligament tissues: Present developments towards successful clinical products. J. Tissue Eng. Regen. Med. 2013, 7, 673–686. [CrossRef]
55. Wang, T.; Gardiner, B.S.; Lin, Z.; Rubenson, J.; Kirk, T.B.; Wang, A.; Xu, J.; Smith, D.W.; Lloyd, D.G.; Zheng, M.H. Bioreactor Design for Tendon/Ligament Engineering. *Tissue Eng. Part B Rev.* 2013, 19, 133–146. [CrossRef]

56. Leong, N.L.; Petriglano, F.A.; McAllister, D.R. Current tissue engineering strategies in anterior cruciate ligament reconstruction. *J. Biomed. Mater. Res. Part A* 2014, 102, 1614–1624. [CrossRef]

57. Yuan, T.; Zhang, C.-Q.; Wang, J.H.-C. Augmenting tendon and ligament repair with platelet-rich plasma (PRP). *Muscle Ligaments Tendons* 2013, 3, 139–149. [CrossRef]

58. Moraes, V.Y.; Lenza, M.; Tamaoki, M.J.S.; Faloppa, F.; Belloti, J.C. Platelet-rich therapies for musculoskeletal soft tissue injuries. *Cochrane Database Syst. Rev.* 2014, 2014, CD007871. [CrossRef]

59. Hogan, M.; Kawakami, Y.; Murawski, C.D.; Fu, F.H. Tissue Engineering of Ligaments for Reconstructive Surgery. *Arthrosc. J. Arthrosc. Relat. Surg.* 2015, 31, 971–979. [CrossRef]

60. Nau, T.; Teuschl, A. Regeneration of the anterior cruciate ligament: Current strategies in tissue engineering. *World J. Orthop.* 2015, 6, 127–136. [CrossRef]

61. Andriolo, L.; Di Matteo, B.; Kon, E.; Filardo, G.; Venieri, G.; Marcacci, M. PRP Augmentation for ACL Reconstruction. *Biores. Int.* 2015, 2015, 371746. [CrossRef] [PubMed]

62. Mace, J.; Wheelton, A.; Khan, W.S.; Anand, S. The Role of Bioreactors in Ligament and Tendon Tissue Engineering. *Curr. Stem Cell Res. Ther.* 2016, 11, 35–40. [CrossRef] [PubMed]

63. Negah Shirazi, A.; Chrzanowski, W.; Khademhosseini, A.; Dehghani, F. Anterior cruciate ligament structure, injuries and regenerative treatments. *Adv. Exp. Med. Biol.* 2015, 881, 161–186. [PubMed]

64. Hexter, A.T.; Thangarajah, T.; Blunn, G.; Haddad, F.S. Biological augmentation of graft healing in anterior cruciate ligament reconstruction: A systematic review. *Bone Jt. J.* 2018, 100-B, 271–284. [CrossRef] [PubMed]

65. Riediger, M.D.; Stride, D.; Coke, S.E.; Kurz, A.Z.; Duong, A.; Ayeni, O.R. ACL Reconstruction with Augmentation: A Scoping Review. *Curr. Rev. Musculoskelet. Med.* 2019, 12, 446–450. [CrossRef]

66. Hevesi, M.; LaPrade, M.; Saris, D.B.F.; Krych, A.J. Stem Cell Treatment for Ligament Repair and Reconstruction. *Curr. Rev. Musculoskelet. Med.* 2019, 12, 446–450. [CrossRef]

67. Lim, W.L.; Liao, L.L.; Ng, M.H.; Chowdhury, S.R.; Law, J.X. Current Progress in Tendon and Ligament Tissue Engineering. *Curr. Rev. Musculoskelet. Med.* 2019, 12, 446–450. [CrossRef]

68. Looney, A.M.; Leider, J.D.; Horn, A.R.; Bodendorfer, B.M. Bioaugmentation in the surgical treatment of anterior cruciate ligament injuries: A review of current concepts and emerging techniques. *SAGE Open Med.* 2020, 8, 2050312120921057. [CrossRef] [PubMed]

69. Chin, A.J.; Goodrich, L.R.; Scimeca, M.S.; Witte, T.; Schnabel, L.V.; Watts, A.E.; Robbins, P.D. Gene Therapy in Musculoskeletal Injury: Novel approaches to improve the current gene delivery systems. *Curr. Gene Ther.* 2005, 5, 37–61. [CrossRef] [PubMed]

70. Yuan, T.; Zhang, C.-Q.; Wang, J.H.-C. Augmenting tendon and ligament repair with platelet-rich plasma (PRP). *Muscle Ligaments Tendons* 2013, 3, 139–149. [CrossRef]

71. Vischer, M.; Lenza, M.; Tamaoki, M.J.S.; Faloppa, F.; Belloti, J.C. Platelet-rich therapies for musculoskeletal soft tissue injuries. *Cochrane Database Syst. Rev.* 2014, 2014, CD007871. [CrossRef]

72. Hogan, M.; Kawakami, Y.; Murawski, C.D.; Fu, F.H. Tissue Engineering of Ligaments for Reconstructive Surgery. *Arthrosc. J. Arthrosc. Relat. Surg.* 2015, 31, 971–979. [CrossRef]

73. Nau, T.; Teuschl, A. Regeneration of the anterior cruciate ligament: Current strategies in tissue engineering. *World J. Orthop.* 2015, 6, 127–136. [CrossRef]

74. Andriolo, L.; Di Matteo, B.; Kon, E.; Filardo, G.; Venieri, G.; Marcacci, M. PRP Augmentation for ACL Reconstruction. *Biores. Int.* 2015, 2015, 371746. [CrossRef] [PubMed]

75. Mace, J.; Wheelton, A.; Khan, W.S.; Anand, S. The Role of Bioreactors in Ligament and Tendon Tissue Engineering. *Curr. Stem Cell Res. Ther.* 2016, 11, 35–40. [CrossRef] [PubMed]

76. Negah Shirazi, A.; Chrzanowski, W.; Khademhosseini, A.; Dehghani, F. Anterior cruciate ligament structure, injuries and regenerative treatments. *Adv. Exp. Med. Biol.* 2015, 881, 161–186. [PubMed]

77. Hexter, A.T.; Thangarajah, T.; Blunn, G.; Haddad, F.S. Biological augmentation of graft healing in anterior cruciate ligament reconstruction: A systematic review. *Bone Jt. J.* 2018, 100-B, 271–284. [CrossRef] [PubMed]

78. Chahla, J.; Kennedy, M.L.; Aman, Z.S.; LaPrade, R.F. Ortho-Biologics for Ligament Repair and Reconstruction. *Clin. Sport. Med.* 2019, 38, 97–107. [CrossRef]

79. Andriolo, L.; Di Matteo, B.; Kon, E.; Filardo, G.; Venieri, G.; Marcacci, M. PRP Augmentation for ACL Reconstruction. *Biores. Int.* 2015, 2015, 371746. [CrossRef] [PubMed]

80. Mace, J.; Wheelton, A.; Khan, W.S.; Anand, S. The Role of Bioreactors in Ligament and Tendon Tissue Engineering. *Curr. Stem Cell Res. Ther.* 2016, 11, 35–40. [CrossRef] [PubMed]

81. Negah Shirazi, A.; Chrzanowski, W.; Khademhosseini, A.; Dehghani, F. Anterior cruciate ligament structure, injuries and regenerative treatments. *Adv. Exp. Med. Biol.* 2015, 881, 161–186. [PubMed]

82. Hexter, A.T.; Thangarajah, T.; Blunn, G.; Haddad, F.S. Biological augmentation of graft healing in anterior cruciate ligament reconstruction: A systematic review. *Bone Jt. J.* 2018, 100-B, 271–284. [CrossRef] [PubMed]

83. Chahla, J.; Kennedy, M.L.; Aman, Z.S.; LaPrade, R.F. Ortho-Biologics for Ligament Repair and Reconstruction. *Clin. Sport. Med.* 2019, 38, 97–107. [CrossRef]
116. Anderson, D.M.; Arredondo, J.; Hahn, K.; Valente, G.; Martin, J.F.; Wilson-Rawls, J.; Rawls, A. Mohawk is a novel homeobox gene expressed in the developing mouse embryo. Dev. Dyn. 2006, 235, 792–801. [CrossRef]

117. Shukunami, C.; Takimoto, A.; Oro, M.; Hiraki, Y. Scleraxis positively regulates the expression of tenomodulin, a differentiation marker of tenocytes. Dev. Biol. 2006, 298, 234–247. [CrossRef]

118. Liu, H.; Zhu, S.; Zhang, C.; Lu, P.; Hu, J.; Yin, Z.; Ma, Y.; Chen, X.; OuYang, H. Crucial transcription factors in tendon development and differentiation: Their potential for tendon regeneration. Cell Tissue Res. 2014, 356, 287–298. [CrossRef]

119. Asahara, H.; Inui, M.; Lotz, M.K. Tendons and Ligaments: Connecting Developmental Biology to Musculoskeletal Disease Pathogenesis. J. Bone Miner. Res. 2017, 32, 1773–1782. [CrossRef]

120. Bobzin, L.; Roberts, R.R.; Chen, H.-J.; Crump, J.G.; Merrill, A.E. Development and maintenance of tendons and ligaments. Development 2021, 148, dev186916. [CrossRef]

121. Zantino, T.; Petersen, W.; Sekiya, J.K.; Musahl, V.; Fu, F.H. Anterior cruciate ligament anatomy and function relating to anatomical reconstruction. Knee Surg. Sport. Traumatol. Arthrosc. 2006, 14, 982–992. [CrossRef] [PubMed]

122. Lessim, S.; Mignonney, V.; Thoreux, P.; Lutomski, D.; Changotade, S. PolyNaSS bioactivation of LARS artificial ligament promotes human ligament fibroblast colonisation in vitro. Bio-Med. Mater. Eng. 2013, 23, 289–297. [CrossRef] [PubMed]

123. Brodsky, J.W.; Schneider, C. Diabetic foot infections. Orthop. Clin. N. Am. 1991, 22, 473–489. [CrossRef]

124. Carpenter, J.E.; Thomopoulos, S.; Soslowski, L.J. Animal Models of Tendon and Ligament Injuries for Tissue Engineering Applications. Clin. Orthop. Relat. Res. 1999, 367, S296–S311. [CrossRef] [PubMed]

125. Woo, S.L.-Y.; Hildebrand, K.; Watanabe, N.; Fenwick, J.A.; Papageorgiou, C.D.; Wang, J.H.-C. Tissue Engineering of Ligament and Tendon Healing. Clin. Orthop. Relat. Res. 2009, 367, S312–S323. [CrossRef] [PubMed]

126. Goh, J.C.-H.; Ouyang, H.-W.; Teoh, S.-H.; Chan, C.K.; Lee, E.-H. Tissue-Engineering Approach to the Repair and Regeneration of Tendons and Ligaments. Tissue Eng. 2003, 9, 31–44. [CrossRef]

127. Laurencin, C.T.; Khan, Y.; Kofron, M.; El-Amin, S.; Botchwey, E.; Yu, X.; Cooper, J.A., Jr. The ABJS Nicolas Andry Award: Tissue engineering of bone and ligament: A 15-year perspective. Clin. Orthop. Relat. Res. 2006, 447, 221–236. [CrossRef]

128. Doroski, D.M.; Brink, K.S.; Temenoff, J.S. Techniques for biological characterization of tissue-engineered tendon and ligament. Biomaterials 2007, 28, 187–202. [CrossRef]

129. Freed, L.E.; Guilak, F.; Guo, X.E.; Gray, M.L.; Tranquillo, R.; Holmes, J.W.; Radisic, M.; Sefton, M.V.; Kaplan, D.; Vunjak-Novakovic, G. Advanced Tools for Tissue Engineering: Scaffold, Bioreactors, and Signaling. Tissue Eng. 2006, 12, 3285–3305. [CrossRef]

130. Mikos, A.G.; Herring, S.W.; Ochareon, P.; Elisseff, J.; Lu, H.H.; Kandel, R.; Schoen, F.J.; Toner, M.; Mooney, D.; Atala, A.; et al. Engineering Complex Tissues. Tissue Eng. 2006, 12, 3307–3339. [CrossRef]

131. Altman, G.H.; Horan, R.L.; Weitzel, P.; Oro, M.; Hiraki, Y. Scleraxis positively regulates the expression of tenomodulin, a differentiation marker of tenocytes. Dev. Dyn. 2006, 235, 792–801. [CrossRef]

132. Vieira, A.; Guedes, R.; Marques, A. Development of ligament tissue biodegradable devices: A review. J. Biomech. 2009, 3, 473–489. [CrossRef]

133. Vavken, P.; Khan, Y.; Kofron, M.; El-Amin, S.; Botchwey, E.; Yu, X.; Cooper, J.A., Jr. The ABJS Nicolas Andry Award: Tissue engineering of bone and ligament: A 15-year perspective. Clin. Orthop. Relat. Res. 2006, 447, 221–236. [CrossRef]

134. Silva, S.S.; Mano, J.F.; Reis, R.L. Potential applications of natural origin polymer-based systems in soft tissue regeneration. Crit. Rev. Biotechnol. 2010, 30, 200–221. [CrossRef]

135. Atala, A.; Kasper, F.K.; Mikos, A.G. Engineering Complex Tissues. Sci. Transl. Med. 2012, 4, 160rv12. [CrossRef]

136. Muller, B.; Bowman, K.F.; Bedi, A. ACL Graft Healing and Biologics. Clin. Sport. Med. 2013, 32, 93–109. [CrossRef]

137. Middleton, K.K.; Barro, V.; Muller, B.; Terada, S.; Fu, F.H. Evaluation of the effects of platelet-rich plasma (PRP) therapy involved in the healing of sports-related soft tissue injuries. Iowa Orthop. J. 2012, 32, 150–163.

138. Hutchinson, I.D.; Rodeo, S.A.; Perrone, G.S.; Murray, M.M. Can platelet-rich plasma enhance anterior cruciate ligament repair? J. Am. Acad. Orthop. Surg. 2008, 16, 177–187. [CrossRef]

139. Teh, T.K.H.; Goh, J.C.H.; Toh, S.L. Controlled Bioactive Molecules Delivery Strategies for Tendon and Ligament Tissue Engineering using Polymeric Nanofibers. Curr. Pharm. Des. 2015, 21, 1991–2005. [CrossRef]

140. Mengsteab, P.Y.; Pereira, H.; De Girolamo, L.; Cucchiarini, M.; Espregueira-Mendes, J.; Reis, R.L.; Oliveira, J.M. Orthopaedic regenerative tissue engineering en route to the holy grail: Disequilibrium between the demand and the supply in the operating room. J. Exp. Orthop. 2018, 5, 14. [CrossRef] [PubMed]

141. Cengiz, I.F.; Pereira, H.; Espregueira-Mendes, J.; Reis, R.L.; Oliveira, J.M. The clinical use of biologics in the knee lesions: Does the patient benefit? Curr. Rev. Musculoskelet. Med. 2019, 12, 406–414. [CrossRef] [PubMed]

142. Mahapatra, P.; Horriat, S.; Anand, B.S. Anterior cruciate ligament repair—Past, present and future. J. Exp. Orthop. 2018, 5, 20. [CrossRef] [PubMed]

143. No, Y.J.; Castilho, M.; Ramaswamy, Y.; Zreiqat, H. Role of Biomaterials and Controlled Architecture on Tendon/Ligament Repair and Regeneration. Adv. Mater. 2020, 32, e1904511. [CrossRef]

144. Liu, R.; Zhang, S.; Chen, X. Injectable hydrogels for tendon and ligament tissue engineering. J. Tissue Eng. Regen. Med. 2020, 14, 1333–1348. [CrossRef]
170. Altman, G.H.; Lu, H.H.; Horan, R.L.; Calabro, T.; Ryder, D.; Kaplan, D.L.; Stark, P.; Martin, I.; Richmond, J.C.; Vunjak-Novakovic, G. Advanced Bioreactor with Controlled Application of Multi-Dimensional Strain for Tissue Engineering. J. Biomech. Eng. 2002, 124, 742–749. [CrossRef]

171. Chen, J.; Altman, G.H.; Karageorgiou, V.; Horan, R.; Collette, A.; Volloch, V.; Colabro, T.; Kaplan, D.L. Human bone marrow stromal cell and ligament fibroblast responses on RGD-modified silk fibers. J. Biomed. Mater. Res. 2003, 67A, 359–570. [CrossRef]

172. Moreau, J.E.; Chen, J.; Horan, R.L.; Kaplan, D.L.; Altman, G.H. Sequential Growth Factor Application in Bone Marrow Stromal Cell Ligament Engineering. Tissue Eng. 2005, 11, 1887–1897. [CrossRef]

173. Liu, H.; Ge, Z.; Wang, Y.; Toh, S.L.; Suthikham, V.; Goh, J.C.H. Modification of sericin-free silk fibers for ligament tissue engineering application. J. Biomed. Mater. Res. Part B Appl. Biomater. 2007, 82B, 129–138. [CrossRef]

174. Chen, J.; Horan, R.L.; Bramono, D.; Moreau, J.E.; Wang, Y.; Geuss, L.R.; Collette, A.L.; Volloch, V.; Altman, G.H. Monitoring Mesenchymal Stromal Cell Developmental Stage to Apply On-Time Mechanical Stimulation for Ligament Tissue Engineering. Tissue Eng. 2006, 12, 3085–3095. [CrossRef]

175. Liu, H.; Fan, H.; Wang, Y.; Toh, S.L.; Goh, J.C. The interaction between a combined knitted silk scaffold and microporous silk sponge with human mesenchymal stem cells for ligament tissue engineering. Biomaterials 2008, 29, 662–674. [CrossRef]

176. Liu, H.; Fan, H.; Toh, S.L.; Goh, J.C. A comparison of rabbit mesenchymal stem cells and anterior cruciate ligament fibroblasts responses on combined silk scaffolds. Biomaterials 2008, 29, 1443–1453. [CrossRef]

177. Lin, V.S.; Lee, M.C.; O'Neal, S.; McKean, J.; Sung, K.-L.P. Ligament Tissue Engineering Using Synthetic Biodegradable Fiber Scaffolds. Tissue Eng. Part C Methods 2011, 17, 687–703. [CrossRef] [PubMed]

178. Seo, Y.-K.; Yoon, H.-H.; Song, K.-Y.; Kwon, S-Y.; Lee, H.-S.; Park, Y.-S.; Park, J.-K. Increase in cell migration and angiogenesis in a composite silk scaffold for tissue-engineered ligaments. J. Orthop. Res. 2009, 27, 495–503. [CrossRef]

179. Horan, R.; Toponarski, I.; Boepple, H.; Weitzel, P.; Richmond, J.; Altman, G. Design and Characterization of a Scaffold for Anterior Cruciate Ligament Engineering. J. Knee Surg. 2009, 22, 82–92. [CrossRef]

180. Li, X.; Snedeker, J. Wired silk architectures provide a biomimetic ACL tissue engineering scaffold. J. Biomech. Eng. 2009, 131, 3085–3095. [CrossRef] [PubMed]

181. Teh, T.K.; Toh, S.L.; Goh, J.C. Aligned hybrid silk scaffold for enhanced differentiation of mesenchymal stem cells into ligament scaffolds. Biomaterials 2009, 30, 4967–4978. [CrossRef]

182. Teuschl, A.; Heimel, P.; Nurnberger, S.; van Giessen, M.; Redl, H.; Nau, T. A novel silk-based scaffold for ligament regeneration and scaffold in large animal model. Biomaterials 2009, 30, 4967–4977. [CrossRef]

183. Cooper, J.A.; Bailey, L.O.; Cartier, J.N.; Castiglioni, C.E.; Kofron, M.D.; Ko, F.K.; Laurencin, C.T. Evaluation of the anterior cruciate ligament: Histological results from a study in sheep. Am. J. Sports Med. 2016, 44, 1547–1557. [CrossRef] [PubMed]

184. Cooper, J.A.; Lu, H.H.; Ko, F.K.; Freeman, J.W.; Laurencin, C.T. Fiber-based tissue-engineered scaffold for ligament replacement: Design considerations and in vitro evaluation. Biomaterials 2005, 26, 1523–1532. [CrossRef]

185. Cooper, J.A.; Bailey, L.O.; Cartier, J.N.; Castiglioni, C.E.; Kofron, M.D.; Ko, F.K.; Laurencin, C.T. Evaluation of the anterior cruciate ligament, medial collateral ligament, achilles tendon and patellar tendon as cell sources for tissue-engineered ligament. Biomaterials 2006, 27, 2747–2754. [CrossRef]

186. Heckl, K.; Schlenker, H.-J.; Fiedler, J.; Brenner, R.; Dauner, M.; Bergenthal, G.; Mattes, T.; Claes, L.; Ignatius, A. Human mesenchymal progenitor cell responses to a novel textured poly(L-lactide) scaffold for ligament tissue engineering. J. Biomed. Mater. Res. Part B Appl. Biomater. 2007, 81B, 82–90. [CrossRef]

187. Freeman, J.W.; Woods, M.D.; Laurencin, C.T. Tissue engineering of the anterior cruciate ligament using a braid–twist scaffold design. J. Biomech. 2007, 40, 2029–2036. [CrossRef]

188. Freeman, J.W.; Woods, M.D.; Cromer, D.A.; Wright, L.D.; Laurencin, C.T. Tissue Engineering of the Anterior Cruciate Ligament: The Viscoelastic Behavior and Cell Viability of a Novel Braid–Twist Scaffold. J. Biomat. Sci. Polym. Ed. 2009, 20, 1709–1728. [CrossRef]

189. Kreja, L.; Liedert, A.; Schlenker, H.; Brenner, R.E.; Fiedler, J.; Friemert, B.; Dürsel, L.; Ignatius, A. Effects of mechanical strain on human mesenchymal stem cells and ligament fibroblasts in a textured poly(L-lactide) scaffold for ligament tissue engineering. J. Mater. Sci. Mater. Med. 2012, 23, 2575–2582. [CrossRef]
195. Araque-Monró, M.C.; Gamboa-Martínez, T.C.; Gil Santos, L.; Bernabé, S.G.; Pradas, M.M.; Estellés, J.M. New concept for a regenerative and resorbable prosthetic for tendon and ligament: Physicochemical and biological characterization of PLA-braided biomaterial. J. Biomed. Mater. Res. Part A 2013, 101, 3228–3237. [CrossRef]

196. Van Eijk, F.; Saris, D.; Riesel, J.; Willems, W.; Van Blitterswijk, C.; Verbout, A.; Dhert, W.; Van Blitterswijk, C. Tissue Engineering of Ligaments: A Comparison of Bone Marrow Stromal Cells, Anterior Cruciate Ligament, and Skin Fibroblasts as Cell Source. Tissue Eng. 2004, 10, 893–903. [CrossRef]

197. Sahoo, S.; Ouyang, H.; Goh, J.C.-H.; Tay, T.; Toh, S. Characterization of a Novel Polymeric Scaffold for Potential Application in Tendon/Ligament Tissue Engineering. Tissue Eng. 2006, 12, 91–99. [CrossRef]

198. Jenner, J.; Van Eijk, F.; Saris, D.; Willems, W.; Dhert, W.; Cremers, L. Effect of Transforming Growth Factor-Beta and Growth Differentiation Factor-5 on Proliferation and Matrix Production by Human Bone Marrow Stromal Cells Cultured on Braided Poly Lactic-Co-Glycolic Acid Scaffolds for Tissue Tissue Engineering. Tissue Eng. 2007, 13, 1573–1582. [CrossRef]

199. Petrigliano, F.A.; English, C.S.; Barba, D.; Esmende, S.; Wu, B.M.; McAllister, D.R. The Effects of Local bFGF Release and Uniaxial Strain on Cellular Adaptation and Gene Expression in a 3D Environment: Implications for Ligament Tissue Engineering. Tissue Eng. 2007, 13, 2721–2731. [CrossRef]

200. Shao, H.J.; Chen, C.S.; Lee, Y.T.; Wang, J.H.; Young, T.H. The phenotypic responses of human anterior cruciate ligament cells cultured on poly(epsilon-caprolactone) and chitosan. J. Biomed. Mater. Res. A 2010, 93, 1297–1305.

201. Peach, M.S.; Kumbar, S.G.; James, R.; Toti, U.S.; Balasubramanium, D.; Deng, M.; Uleri, B.; Mazzocca, A.D.; McCarthy, M.B.; Morozowich, N.L.; et al. Design and optimization of polyphosphazene functionalized fiber matrices for soft tissue regeneration. J. Biomed. Nanotechnol. 2012, 8, 107–124. [CrossRef] [PubMed]

202. Huot, S.; Rohman, G.; Rifflaut, M.; Pinzano, A.; Grossin, L.; Migonney, V. Increasing the bioactivity of elastomeric poly(epsilon-caprolactone) scaffolds for use in tissue engineering. Biomed Eng. 2013, 23, 281–288. [PubMed]

203. Leong, N.L.; Kabir, N.; Arshi, A.; Nazemi, A.; Wu, B.; Petrigliano, F.A.; McAllister, D.R. Evaluation of Polycaprolactone Scaffold with Basic Fibroblast Growth Factor and Fibroblasts in an Athymic Rat Model for Anterior Cruciate Ligament Reconstruction. Tissue Eng. Part A 2015, 21, 1859–1868. [CrossRef] [PubMed]

204. Leroux, A.; Egles, C.; Migonney, V. Impact of chemical and physical treatments on the mechanical properties of poly(epsilon-caprolactone) fibers bundles for the anterior cruciate ligament reconstruction. PLoS ONE 2018, 13, e0205722. [CrossRef] [PubMed]

205. Leroux, A.; Venkatesan, J.K.; Castner, D.G.; Cucchiari, M.; Migonney, V. Analysis of early cellular responses of anterior cruciate ligament fibroblasts seeded on different molecular weight polycaprolactone films functionalized by a bioactive poly(sodium styrene sulfonate) polymer. Biointerphases 2019, 14, 041004. [CrossRef] [PubMed]

206. Leroux, A.; Nguyen, T.N.; Rangel, A.; Cacciapuoti, I.; Duprez, D.; Castner, D.G.; Migonney, V. Long-term hydrolytic degradation study of polycaprolactone films and fibers grafted with poly(sodium styrene sulfonate): Mechanism study and cell response. Biointerphases 2020, 15, 061006. [CrossRef] [PubMed]

207. Doroski, D.M.; Leventon, M.; Temenoff, J.S. Cyclic Tensile Culture Promotes Fibroblastic Differentiation of Marrow Stromal Cells Encapsulated in Poly(Ethylene Glycol)-Based Hydrogels. Tissue Eng. Part A 2010, 16, 3457–3466. [CrossRef]

208. Ciobanu, M.; Siove, A.; Gueguen, V.; Gamble, L.J.; Castner, A.D.G.; Migonney, V. Radical Graft Polymerization of Styrene Sulfonate Lactic-Co-Glycolic Acid Scaffolds for Use in Tissue Engineering. J. Biomed. Mater. Res. Part A 2013, 257–265. [CrossRef]

209. Zhou, J.; Ciobanu, M.; Pavon-Djavid, G.; Gueguen, V.; Migonney, V. Morphology and adhesion of human fibroblast cells cultured on bioactive polymer grafted ligament prostheses. Annu. Int. Conf. IEEE Eng. Med. Biol. Soc. 2007, 2007, 5115–5118.

210. Vaquette, C.; Viateau, V.; Guérard, S.; Anagnostou, F.; Manassero, M.; Castner, D.G.; Migonney, V. The effect of polystyrene sodium sulfonate grafting on polyethylene terephthalate artificial ligaments on in vitro mineralisation and in vivo bone tissue integration. Biomaterials 2013, 34, 7048–7063. [CrossRef]

211. Nguyen, T.N.; Rangel, A.; Grainger, D.W.; Migonney, V. Influence of spin finish on degradation, functionalization and long-term storage of polyethylene terephthalate fabrics dedicated to ligament prostheses. Sci. Rep. 2021, 11, 4258. [CrossRef]

212. Murray, M.M.; Martin, S.D.; Spector, M. Migration of cells from human anterior cruciate ligament explants into collagen-glycosaminoglycan scaffolds. J. Orthop. Res. 2000, 18, 557–564. [CrossRef]

213. Murray, M.M.; Spector, M. The migration of cells from the ruptured human anterior cruciate ligament into collagen-glycosaminoglycan regeneration templates in vitro. Biomaterials 2001, 22, 2393–2402. [CrossRef]

214. Panas-Perez, E.; Gatt, C.J.; Dunn, M.G. Development of a silk and collagen fiber scaffold for anterior cruciate ligament reconstruction. J. Mater. Sci. Mater. Electron. 2013, 24, 257–265. [CrossRef]

215. Shen, W.; Chen, X.; Hu, Y.; Yin, Z.; Zhu, T.; Hu, J.; Chen, J.; Zheng, Z.; Zhang, W.; Ran, J.; et al. Long-term effects of knitted silk-collagen sponge scaffold on anterior cruciate ligament reconstruction and osteoarthritis prevention. Biomaterials 2014, 35, 8154–8163. [CrossRef]

216. Bi, F.; Shi, Z.; Liu, A.; Guo, P.; Yan, S. Anterior Cruciate Ligament Reconstruction in a Rabbit Model Using Silk-Collagen Scaffold and Comparison with Autograft. PLoS ONE 2015, 10, e0125900. [CrossRef]
243. Elsner, C.; Bohne, J. The retroviral vector family: Something for everyone. Virus Genes 2017, 53, 714–722. [CrossRef] [PubMed]

244. Milone, M.C.; O'Doherty, U. Clinical use of lentiviral vectors. Leukemia 2018, 32, 1529–1541. [CrossRef] [PubMed]

245. Li, C.; Samulski, R.J. Engineering adeno-associated virus vectors for gene therapy. Nat. Rev. Genet. 2020, 21, 255–272. [CrossRef] [PubMed]

246. Maurer, A.C.; Weitzman, M.D. Adeno-Associated Virus Genome Interactions Important for Vector Production and Transduction. Hum. Gene Ther. 2020, 31, 499–511. [CrossRef] [PubMed]

247. Cottard, V.; Valvason, C.; Falgarone, G.; Lutomski, D.; Boissier, M.-C.; Bessis, N. Immune Response Against Gene Therapy Vectors: Influence of Synovial Fluid on Adeno-Associated Virus Mediated Gene Transfer to Chondrocytes. J. Clin. Immunol. 2004, 24, 162–169. [CrossRef]

248. Mingozzi, F.; Chen, Y.; Edmonson, S.; Zhou, S.; Thrulings, R.M.; Tak, P.P.; High, K.; Vervoordeldonk, M.J. Prevalence and pharmacological modulation of humoral immunity to AAV vectors in gene transfer to synovial tissue. Gene Ther. 2013, 20, 417–424. [CrossRef]

249. Verdera, H.C.; Kuranda, K.; Mingozzi, F. AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer. Mol. Ther. 2020, 28, 723–746. [CrossRef]

250. Murphy, P.G.; Loitz, B.J.; Frank, C.B.; Hart, D.A. Influence of exogenous growth factors on the synthesis and secretion of collagen types I and III by explants of normal and healing rabbit ligaments. Biochem. Cell Biol. 1994, 72, 403–409. [CrossRef]

251. Schmidt, C.C.; Georgescu, H.I.; Kwok, C.K.; Blomstrom, G.L.; Engle, C.P.; Larkin, L.A.; Evans, C.H.; Woo, S.L.-Y. Effect of growth factors on the proliferation of fibroblasts from the medial collateral and anterior cruciate ligaments. J. Orthop. Res. 1995, 13, 184–190. [CrossRef]

252. Desrosiers, E.A.; Yahia, L.; Rivard, C.-H. Proliferative and matrix synthesis response of canine anterior cruciate ligament fibroblasts submitted to combined growth factors. J. Orthop. Res. 1996, 14, 200–208. [CrossRef]

253. Spindler, K.P.; Imro, A.K.; Mayes, C.E.; Davidson, J.M. Patellar tendon and anterior cruciate ligament have different mitogenic responses to platelet-derived growth factor and transforming growth factor beta. J. Orthop. Res. 1996, 14, 542–546. [CrossRef]

254. Marui, T.; Niyibizi, C.; Georgescu, H.I.; Cao, M.; Kavalkovich, K.W.; Levine, R.E.; Woo, S.L.-Y. Effect of growth factors on matrix synthesis by ligament fibroblasts. J. Orthop. Res. 1997, 15, 18–23. [CrossRef]

255. Yoshiida, M.; Fujii, K. Differences in cellular properties and responses to growth factors between human ACL and MCL cells. J. Orthop. Sci. 1999, 4, 293–298. [CrossRef]

256. Murray, M.M.; Rice, K.; Wright, R.J.; Spector, M. The effect of selected growth factors on human anterior cruciate ligament cell interactions with a three-dimensional collagen-GAG scaffold. J. Orthop. Res. 2003, 21, 238–244. [CrossRef]

257. Okuzumi, T.; Tohyama, H.; Kondo, E.; Yasuda, K. The effect of cell-based therapy with autologous synovial fibroblasts activated by exogenous TGF-beta1 on the in situ frozen-thawed anterior cruciate ligament. J. Orthop. Sci. 2004, 9, 488–494. [CrossRef]

258. Kondo, E.; Yasuda, K.; Yamanaka, M.; Minami, A.; Tohyama, H. Effects of Administration of Exogenous Growth Factors on Biomechanical Properties of the Elongation-type Anterior Cruciate Ligament Injury with Partial Laceration. Am. J. Sport. Med. 2005, 33, 188–196. [CrossRef]

259. Wolfman, A.C.; Weitzman, M.D. Adeno-Associated Virus Genome Interactions Important for Vector Production and Transduction. Hum. Gene Ther. 2020, 31, 499–511. [CrossRef] [PubMed]

260. Letson, A.K.; Dahners, L.E. The effect of combinations of growth factors on ligament healing. Am. J. Orthop. 1995, 24, 71–79. [CrossRef]

261. Date, H.; Furumatsu, T.; Sakoma, Y.; Yoshida, A.; Hayashi, Y.; Abe, N.; Ozaki, T. GDF-5/7 and bFGF activate integrin alpha2-betag3-mediated cellular migration in rabbit ligament fibroblasts. J. Orthop. Res. 2017, 35, 225–231. [CrossRef] [PubMed]

262. Amiel, D.; Nagineni, C.N.; Choi, S.H.; Lee, J. Intrinsic properties of ACL and MCL cells and their responses to growth factors. Med. Sci. Sport. Exerc. 1995, 27, 844–851. [CrossRef]

263. Letson, A.K.; Dahners, L.E. The effect of combinations of growth factors on ligament healing. Clin. Orthop. Relat. Res. 1994, 308, 207–212. [CrossRef]

264. Scherping, S.C.; Schmidt, C.C.; Georgescu, H.I.; Kwok, C.K.; Evans, C.H.; Woo, S.L.-Y. Effect of Growth Factors on the Proliferation of Ligament Fibroblasts from Skeletally Mature Rabbits. Connect. Tissue Res. 1997, 36, 1–8. [CrossRef] [PubMed]

265. Kobayashi, D.; Kurokawa, M.; Yoshiya, S.; Mizuno, K. Effect of basic fibroblast growth factor on the healing of defects in the canine anterior cruciate ligament. Knee Surg. Sport. Traumatol. Arthrosc. 1997, 5, 189–194. [CrossRef]

266. Lee, J.; Green, M.H.; Amiel, D. Synergistic effect of growth factors on cell outgrowth from explants of rabbit anterior cruciate and medial collateral ligaments. J. Orthop. Res. 1995, 13, 435–441. [CrossRef]

267. Weiler, A.; Förster, C.; Hunt, P.; Falk, R.; Jung, U.; Unterhauser, F.N.; Bergmann, V.; Schmidmaier, G.; Haas, N.P. The Influence of Locally Applied Platelet-Derived Growth Factor-BB on Free Tendon Graft Remodeling after Anterior Cruciate Ligament Reconstruction. Am. J. Sport. Med. 2004, 32, 881–891. [CrossRef]

268. McKeon, J.M.; Hsieh, A.H.; Sung, K.L.P. Epidermal growth factor differentially affects integrin-mediated adhesion and proliferation of ACL and MCL fibroblasts. Biotherapy 2004, 41, 139–152. [CrossRef]
270. Woo, Y.K.; Kwon, S.Y.; Lee, H.S.; Park, Y.S. Proliferation of anterior cruciate ligament cells in vitro by photo-immobilized epidermal growth factor. *J. Orthop. Res.* 2007, 25, 73–80. [CrossRef]

271. Ju, Y.-J.; Tohyama, H.; Kondo, E.; Yoshikawa, T.; Muneta, T.; Shinomiya, K.; Yasuda, K. Effects of Local Administration of Vascular Endothelial Growth Factor on Properties of the in Situ Frozen-Thawed Anterior Cruciate Ligament in Rabbits. *Am. J. Sport. Med.* 2006, 34, 84–91. [CrossRef]

272. Yoshikawa, T.; Tohyama, H.; Katsura, T.; Kondo, E.; Kotani, Y.; Matsumoto, H.; Toyama, Y.; Yasuda, K. Effects of Local Administration of Vascular Endothelial Growth Factor on Mechanical Characteristics of the Semitendinosus Tendon Graft after Anterior Cruciate Ligament Reconstruction in Sheep. *Am. J. Sport. Med.* 2006, 34, 1918–1925. [CrossRef]

273. Caceres, M.D.; Pfeifer, C.G.; Docheva, D. Understanding Tendons: Lessons from Transgenic Mouse Models. *Stem Cells Dev.* 2018, 27, 1161–1174. [CrossRef]

274. Murchison, N.D.; Price, B.A.; Conner, D.A.; Keene, D.R.; Olson, E.N.; Tabin, C.J.; Schweitzer, R. Regulation of tendon differentiation by scleraxis distinguishes force-transmitting tendons from muscle-anchoring tendons. *Development* 2007, 134, 2709–2708. [CrossRef]

275. Alberton, P.; Popov, C.; Prägert, M.; Kohler, J.; Shukunami, C.; Schieker, M.; Docheva, D. Conversion of Human Bone Marrow-Derived Mesenchymal Stem Cells into Tendon Progenitor Cells by Ectopic Expression of Scleraxis. *Stem Cells Dev.* 2012, 21, 846–858. [CrossRef]

276. Chen, X.; Yin, Z.; Chen, J.-L.; Shen, W.-L.; Liu, H.-H.; Tang, Q.-M.; Fang, Z.; Lu, L.-R.; Ji, J.; Ouyang, H.-W. Force and scleraxis synergistically promote the commitment of human ES cells derived MSCs to tenocytes. *Sci. Rep.* 2012, 2, 977. [CrossRef]

277. Dyment, N.A.; Liu, C.-F.; Kazemi, N.; Aschbacher-Smith, L.E.; Kenter, K.; Breidenbach, A.P.; Shearm, J.T.; Wylie, C.; Rowe, D.W.; Butler, D.L. The Paratenon Contributes to Scleraxis-Expressing Cells during Patellar Tendon Healing. *PLoS ONE* 2013, 8, e59944. [CrossRef]

278. Nichols, A.E.; Werre, S.R.; Dahlgren, L.A. Transient Scleraxis Overexpression Combined with Cyclic Strain Enhances Ligament Cell Differentiation. *Tissue Eng. Part A* 2018, 24, 1444–1455. [CrossRef]

279. Zhu, X.; Liu, Z.; Wu, S.; Li, Y.; Xiong, H.; Zou, G.; Jin, Y.; Yang, J.; You, Q.; Zhang, J.; et al. Enhanced tenogenic differentiation and tendon-like tissue formation by Scleraxis overexpression in human amniotic mesenchymal stem cells. *Histochem. J.* 2020, 51, 209–220. [CrossRef]

280. Ito, Y.; Toriuchi, N.; Yoshytaka, T.; Ueno-Kudoh, H.; Sato, T.; Yokoyama, S.; Nishida, K.; Akimoto, T.; Takahashi, M.; Miyaki, S.; et al. The *Mohawk* homeobox gene is a critical regulator of tendon differentiation. *Proc. Natl. Acad. Sci. USA* 2010, 107, 10538–10542. [CrossRef]

281. Nakahara, H.; Hasegawa, A.; Otabe, K.; Ayabe, F.; Matsukawa, T.; Onizuka, N.; Ito, Y.; Ozaki, T.; Lotz, M.K.; Asahara, H. Transcription Factor Mohawk and the Pathogenesis of Human Anterior Cruciate Ligament Degradation. *Arthritis Care Res.* 2013, 65, 2081–2089. [CrossRef] [PubMed]

282. Otabe, K.; Nakahara, H.; Hasegawa, A.; Matsukawa, T.; Ayabe, F.; Onizuka, N.; Inui, M.; Takada, S.; Ito, Y.; Sekiya, I.; et al. Transcription factor Mohawk controls tenogenic differentiation of bone marrow mesenchymal stem cells in vitro and in vivo. *J. Orthop. Res.* 2015, 33, 1–8. [CrossRef] [PubMed]

283. Kato, K.; Kurimoto, R.; Tsutsumi, H.; Chiba, T.; Kato, T.; Shishido, K.; Kato, M.; Ito, Y.; Cho, Y.; Hoshi, O.; et al. In vitro Neo-Genesis of Tendon/Ligament-Like Tissue by Combination of Mohawk and a Three-Dimensional Cyclic Mechanical Stretch Culture System. *Front. Cell Dev. Biol.* 2020, 8, 307. [CrossRef]

284. Cameron, M.L.; Fu, F.H.; Paessler, H.H.; Schneider, M.R.; Evans, C.H. Synovial fluid cytokine concentrations as possible prognostic indicators in the ACL-deficient knee. *Knee Surg. Sport. Traumatol. Arthrosc.* 1994, 2, 38–44. [CrossRef] [PubMed]

285. Lohmander, L.S.; Roos, H.; Dahlberg, L.; Hoerrner, L.A.; Lark, M.W. Temporal patterns of stromelysin-1, tissue inhibitor, and tissue inhibitors of metalloproteinases in anterior cruciate ligament and medial collateral ligament fibroblasts after a mechanical injury: Involvement of the p65 subunit of NF-kappaB. *Wound Repair Regen.* 2009, 17, 709–716. [CrossRef]

286. Fry, J.; Wang, C.; Yin, L.; Xu, C.; Zhang, Y.; Sung, K.-L.P. Interleukin-1 beta influences on lysyl oxidases and matrix metalloproteinas profile of injured anterior cruciate ligament and medial collateral ligament fibroblasts. *Int. Orthop.* 2013, 37, 495–505. [CrossRef]

287. Bigoni, M.; Sacerdote, P.; Turati, M.; Franchi, S.; Gandolla, M.; Gaddi, D.; Moretti, S.; Munegato, D.; Augusti, C.A.; Bresciani, E.; et al. Acute and late changes in intraarticular cytokine levels following anterior cruciate ligament injury. *J. Orthop. Res.* 2013, 31, 315–321. [CrossRef]
292. Xie, J.; Jiang, J.; Huang, W.; Zhang, Y.; Xu, C.; Wang, C.; Yin, L.; Chen, P.C.; Sung, K.P. TNF-α induced down-regulation of lysyl oxidase activity in anterior cruciate ligament and medial collateral ligament fibroblasts. *Knee* 2014, 21, 47–53. [CrossRef]

293. Struglics, A.; Larsson, S.; Kumahashi, N.; Frobell, R.; Lohmander, L.S. Changes in cytokines and aggrecan ARGS neoeptope in synovial fluid and serum and in C-terminal crosslinking telopeptide of type II collagen and N-terminal crosslinking telopeptide of type I collagen in urine over five years after anterior cruciate ligament rupture: An exploratory analysis in the knee anterior cruciate ligament, nonsurgical versus surgical treatment trial. *Arthritis Rheumatol.* 2015, 67, 1816–1825.

294. Chamberlain, C.S.; Leiferman, E.M.; Frisch, K.E.; Kuehl, S.; Brickson, S.L.; Murphy, W.L.; Baer, G.S.; Vanderby, R. Interleukin-1 receptor antagonist modulates inflammation and scarring after anterior cruciate ligament injury. *Connect. Tissue Res.* 2014, 55, 177–186. [CrossRef]

295. Chamberlain, C.S.; Leiferman, E.M.; Frisch, K.E.; Brickson, S.L.; Murphy, W.L.; Baer, G.S.; Vanderby, R. Interleukin-1 Receptor Antagonist after Injury and the Effects of Interleukin-1 Receptor Antagonist. *PLoS ONE* 2013, 8, e71631. [CrossRef]

296. Lawrence, J.T.R.; Birmingham, J.; Toth, A.P. Emerging Ideas: Prevention of Posttraumatic Arthritis Through Interleukin-1 and Tumor Necrosis Factor-alpha Inhibition. *Clin. Orthop. Relat. Res.* 2011, 469, 3522–3526. [CrossRef]

297. Kraus, V.B.; Birmingham, J.; Stabler, T.V.; Feng, S.; Taylor, D.C.; Moorman, C.T.; 3rd; Garrett, W.E.; Toth, A.P. Effects of intraarticular IL1-Ra for acute anterior cruciate ligament knee injury: A randomized controlled pilot trial (NCT00332254). *Osteoarthr. Cartil.* 2012, 20, 271–278. [CrossRef]

298. Ricchetti, E.T.; Reddy, S.C.; Ansorge, H.L.; Zgonis, M.H.; Van Kleunen, J.P.; Liechty, K.W.; Soslowsky, L.J.; Beredjiklian, P.K. Effect of Interleukin-10 Overexpression on the Properties of Healing Tendon in a Murine Patellar Tendon Model. *J. Hand Surg.* 2008, 33, 1843–1852. [CrossRef]

299. Rigoni, M.; Zanchi, N.; Omeljaniuk, R.J.; Zatti, G.; Locatelli, V.; Torsello, A.; Turati, M. Role of interleukin-10 in the synovial fluid of the anterior cruciate ligament injured knee. *Eur. Rev. Med. Pharmacol. Sci.* 2019, 23, 932–940.

300. Wang, C.; Sha, Y.; Wang, S.; Chi, Q.; Sung, K.P.; Xu, K.; Yang, L. Lysyl oxidase suppresses the inflammatory response in anterior cruciate ligament fibroblasts and promotes tissue regeneration by targeting myotrophin via the nuclear factor-kappa B pathway. *J. Tissue Eng. Regen. Med.* 2020, 14, 1063–1076. [CrossRef]

301. Sun, M.; Connizzo, B.K.; Adams, S.M.; Freedman, B.R.; Wenstrup, R.J.; Soslowsky, L.J.; Birk, D.E. Targeted Deletion of Collagen V in Tendons and Ligaments Results in an Enhanced Achilles tendon healing by fibromodulin gene transfer. *Clin. Orthop. Relat. Res.* 2015, 185, 1436–1447. [PubMed]

302. Evangelopoulos, D.S.; Kohl, S.; Schwienbacher, S.; Gantenbein, B.; Exadaktylos, A.; Ahmad, S.S. Collagen application reduces complication rates of mid-substance ACL tears treated with dynamic intraligamentary stabilization. *Knee Surg. Sport. Traumatol.* 2017, 25, 2414–2419. [CrossRef] [PubMed]

303. Page, R.L.; Wharton, J.M.; E Wilkinson, H.L.; Zgonis, M.H.; Van Kleunen, J.P.; Liechty, K.W.; Soslowsky, L.J.; Gardiner, P.; Pritchett, E.L.C.; et al. Bidisomide (SC-40230), a new antiarrhythmic agent: Initial study of tolerability and pharmacokinetics. *Clin. Pharmacol. Ther.* 1992, 51, 371–378. [CrossRef] [PubMed]

304. Alberton, P.; Dex, S.; Popov, C.; Shukunami, C.; Schieker, M.; Docheva, D. Loss of Tenomodulin Results in Reduced Self-Renewal and Augmented Senescence of Tendon Stem/Progenitor Cells. *Stem Cells Dev.* 2015, 24, 597–609. [CrossRef] [PubMed]

305. Pritchett, E.L.C.; et al. Bidisomide (SC-40230), a new antiarrhythmic agent: Initial study of tolerability and pharmacokinetics. *Clin. Pharmacol. Ther.* 1992, 51, 371–378. [CrossRef] [PubMed]

306. Yin, H.; Caceres, M.D.; Yan, Z.; Schieker, M.; Nerlich, M.; Docheva, D. Tenomodulin is Required for Tendon Endurance Running and Collagen I Fibril Adaptation to Mechanical Load. *eBioMedicine* 2017, 20, 240–254. [CrossRef]

307. Lewis, J.L.; Krawczak, D.A.; Oegema, T.R.; Westendorf, J.J. Effect of Decorin and Dermatan Sulfate on the Mechanical Properties of a Neocartilage. *Connect. Tissue Res.* 2010, 51, 159–170. [CrossRef]

308. Delalande, A.; Gosselin, M.-P.; Suwalski, A.; Guilmain, W.; Leduc, C.; Baril, P.; Midoux, P.; Pichon, C. Enhanced Achilles tendon healing by fibromodulin gene transfer. *Nanomed. Nanotechnol. Biol. Med.* 2015, 11, 1735–1744. [CrossRef]

309. Robinson, K.A.; Sun, M.; Barnum, C.E.; Weiss, S.N.; Huegel, J.; Shetye, S.S.; Lin, L.; Saez, D.; Adams, S.M.; Iozzo, R.V.; et al. Decorin and biglycan are necessary for maintaining collagen fibril structure, fiber realignment, and mechanical properties of mature tendons. *Matrix Biol.* 2017, 64, 81–93. [CrossRef]

310. Robinson, K.A.; Sun, M.; Barnum, C.E.; Weiss, S.N.; Huegel, J.; Shetye, S.S.; Lin, L.; Saez, D.; Adams, S.M.; Iozzo, R.V.; et al. Decorin and biglycan are necessary for maintaining collagen fibril structure, fiber realignment, and mechanical properties of mature tendons. *Matrix Biol.* 2017, 64, 81–93. [CrossRef]

311. Delalande, A.; Gosselin, M.-P.; Suwalski, A.; Guilmain, W.; Leduc, C.; Berchl, M.; Jaffres, P.; Baril, P.; Midoux, P.; Pichon, C. Enhanced Achilles tendon healing by fibromodulin gene transfer. *Nanomed. Nanotechnol. Biol. Med.* 2015, 11, 1735–1744. [CrossRef]

312. Nakamichi, R.; Asahara, H. Regulation of tendon and ligament differentiation. *Bone* 2021, 143, 115609. [CrossRef]

313. Goomer, R.S.; Maris, T.M.; Gelberman, R.; Boyer, M.; Silva, M.; Amiel, D. Nonviral In Vivo Gene Therapy for Tissue Engineering of Articular Cartilage and Tendon Repair. *Clin. Orthop. Relat. Res.* 2000, 379, S189–S200. [CrossRef]

314. Gerich, T.G.; Kang, R.; Fu, F.H.; Robbins, P.D.; Evans, C.H. Gene transfer to the rabbit patellar tendon: Potential for genetic enhancement of tendon and ligament healing. *Gene Ther.* 1996, 3, 1089–1093.

315. Gerich, T.G.; Kang, R.; Fu, F.H.; Robbins, P.D.; Evans, C.H. Gene transfer to the rabbit patellar tendon. *Knee Surg. Sports Traumatol. Arthrosc.* 1997, 5, 118–123. [CrossRef]
316. Lou, J.; Tu, Y.; Ludwig, F.J.; Zhang, J.; Manske, P.R. Effect of Bone Morphogenetic Protein-12 Gene Transfer on Mesenchymal Progenitor Cells. *Clin. Orthop. Relat. Res.* 1999, 369, 333–339. [CrossRef]

317. Pascher, A.; Steinitz, A.F.; Palmer, G.D.; Betz, O.; Gouze, J.-N.; Gouze, E.; Pilapil, C.; Ghivizzani, S.C.; Evans, C.H.; Murray, M.M. Enhanced Repair of the Anterior Cruciate Ligament by In Situ Gene Transfer: Evaluation in an in Vitro Model. *Mol. Ther.* 2004, 10, 327–336. [CrossRef]

318. Hou, Y.; Mao, Z.; Wei, X.; Lin, L.; Chen, L.; Wang, H.; Fu, X.; Zhang, J.; Yu, C. Effects of transforming growth factor-beta1 and vascular endothelial growth factor genes and its effect on anterior cruciate ligament fibroblasts. *Chin. Med. J.* 2008, 121, 1426–1432. [CrossRef]

319. Majewski, M.; Betz, O.; E Ochsner, P.; Liu, F.; Porter, R.M.; Evans, C.H. Ex vivo adeno viral transfer of bone morphogenetic protein 12 (BMP-12) cDNA improves Achilles tendon healing in a rat model. *Gene Ther.* 2008, 15, 1139–1146. [CrossRef]

320. Kawakami, Y.; Takayama, K.; Matsumoto, T.; Tang, Y.; Mifune, T.; Yamauchi, J.; Greco, N.; Kuroda, R.; Kurosaka, M.; et al. Antisense Gene Inhibition. *Matrix Biol.* 2009, 28, 324–335. [CrossRef] [PubMed]

321. Groth, K.; Berezhanskyy, T.; Aneja, M.K.; Geiger, J.; Schweizer, M.; Maucksch, L.; Pasewald, T.; Brill, T.; Tiganis, B.; Weber, E.; et al. BMP12 and BMP13 gene transfer induce ligamentogenic differentiation in mesenchymal progenitor and anterior cruciate ligament cells. *Cytotherapy* 2010, 12, 505–513. [CrossRef] [PubMed]

322. Haddad-Weber, M.; Prager, P.; Kunz, M.; Seefried, L.; Jakob, F.; Murray, M.M.; Evans, C.H.; Nöth, U.; Steinitz, A.F. BMP12 and BMP13 gene transfer induce ligamentogenic differentiation in mesenchymal progenitor and anterior cruciate ligament cells. *Cytotherapy* 2010, 12, 505–513. [CrossRef] [PubMed]

323. Guolotta, L.V.; Kovacevic, D.; Packer, J.D.; Deng, X.H.; Rodeo, S.A. Bone Marrow-Derived Mesenchymal Stem Cells Transduced with Scleraxis Improve Rotator Cuff Healing in a Rat Model. *Am. J. Sport. Med.* 2011, 39, 1282–1289. [CrossRef] [PubMed]

324. Weber, M.; Kunz, M.; Stehle, J.; Noth, U.; Steinitz, A. BMP-12 transduced MSCs in collagen hydrogel for ligament reconstruction. *J. Stem Cells Regen. Med.* 2007, 2, 72–73. [PubMed]

325. Takayama, K.; Kawakami, Y.; Mifune, Y.; Matsumoto, T.; Tang, Y.; Cummins, J.H.; Greco, N.; Kuroda, R.; Kurosaka, M.; Wang, B.; et al. The effect of blocking angiogenesis on anterior cruciate ligament healing following stem cell transplantation. *Biomaterials* 2015, 60, 9–19. [CrossRef]

326. Kawakami, Y.; Takayama, K.; Matsumoto, T.; Tang, Y.; Wang, B.; Mifune, Y.; Cummins, J.H.; Warth, R.J.; Kuroda, R.; Kurosaka, M.; et al. Anterior Cruciate Ligament-Derived Stem Cells Transduced with BMP2 Accelerate Graft-Bone Integration After ACL Reconstruction. *Am. J. Sport. Med.* 2017, 45, 584–597. [CrossRef]

327. Tsutsumi, H.; Kurimoto, R.; Nakamichi, R.; Chiba, T.; Matsuhashi, T.; Fujii, Y.; Sanada, R.; Kato, T.; Shishido, K.; Sakamaki, Y.; et al. Generation of a tendon-like tissue from human iPSCs. *J. Tissue Eng.* 2022, 13, 20417314221074018. [CrossRef]

328. Madry, H.; Kohn, D.; Cucchiarini, M. Direct FGF-2 Gene Transfer via Recombinant Adeno-Associated Virus Vectors Stimulates Cell Proliferation, Collagen Production, and the Repair of Experimental Lesions in the Human ACL. *Am. J. Sport. Med.* 2012, 41, 194–202. [CrossRef]

329. Nakamura, N.; Hart, D.A.; Frank, C.B.; Marchuk, L.L.; Shrive, N.G.; Ota, N.; Taira, K.; Yoshikawa, H.; Kaneda, Y. Efficient Transfer of Intact Oligonucleotides into the Nucleus of Ligament Scar Fibroblasts by HVJ-Cationic Liposomes Is Correlated with Effective Antisense Gene Inhibition. *J. Biochem.* 2001, 129, 755–759. [CrossRef]

330. Shimomura, T.; Jia, F.; Niyibizi, C.; Woo, S.L. Antisense oligonucleotides reduce synthesis of procollagen alpha1 (V) chain in human patellar tendon fibroblasts: Potential application in healing ligaments and tendons. *Connect. Tissue Res.* 2003, 44, 167–172. [CrossRef]

331. Groth, K.; Berezhanskyy, T.; Aneja, M.K.; Geiger, J.; Schweizer, M.; Maucksch, L.; Pasewald, T.; Brill, T.; Tiganis, B.; Weber, E.; et al. Tendon healing induced by chemically modified mRNAs. *Eur. Cells Mater.* 2017, 33, 294–307. [CrossRef]

332. Chen, X.-H.; Tong, Y.; Xu, W.-L.; Jin, J.; Qian, W.-B. Expression of telomere binding factor 2 (TRF2) on leukemia cell lines and primary leukemia cells. *Zhongguo Da Xue Xue Bao Yi Xue Ban* 2008, 37, 170–175.

333. Li, F.; Jia, H.; Yu, C. ACL reconstruction in a rabbit model using irradiated Achilles allograft seeded with mesenchymal stem cells or PDGF gene-transfected mesenchymal stem cells. *Knee Surg. Sport. Traumatol. Arthrosoc.* 2007, 15, 1219–1227. [CrossRef]

334. Lu, Y.F.; Liu, Y.; Fu, W.M.; Xu, J.; Wang, B.; Sun, Y.X.; Wu, T.Y.; Xu, L.L.; Chan, K.M.; Zhang, J.F.; et al. Long noncoding RNA H19 accelerates tenogenic differentiation and promotes tendon healing through targeting miR-29b-3p and activating TGF-beta1 signaling. *FASEB J.* 2017, 31, 954–964. [CrossRef]

335. Lu, P.; Zhang, G.-R.; Cai, Y.-Z.; Heng, B.C.; Ren, H.; Wang, L.-L.; Ji, J.; Zou, X.-H.; Ouyang, H.-W. Lentiviral-Encoded shRNA Silencing of Proteoglycan Decorin Enhances Tendon Repair and Regeneration within a Rat Model. *Cell Transplant.* 2017, 26, 1507–1517. [CrossRef]

336. Chen, L.; Wang, G.-D.; Liu, J.-P.; Wang, H.-S.; Liu, X.-M.; Wang, Q.; Cai, X.-H. miR-135a modulates tendon stem/progenitor cell senescence via suppressing ROCK1. *Bone* 2015, 71, 210–216. [CrossRef]

337. Nakamura, N.; Horibe, T.; Matsumoto, N.; Tomita, T.; Natsugoe, T.; Kaneda, Y.; Shino, K.; Ochi, T. Transient introduction of a foreign gene into healing rat patellar ligament. *J. Clin. Investig.* 1996, 97, 226–231. [CrossRef]

338. Nakamura, N.; Shino, K.; Natsugoe, T.; Horibe, T.; Matsumoto, N.; Kaneda, Y.; Ochi, T. Early biological effect of in vivo gene transfer of platelet-derived growth factor (PDGF-B) into healing patellar ligament. *Gene Ther.* 1998, 5, 1165–1170. [CrossRef]
366. Weiser, J.R.; Saltzman, W.M. Controlled release for local delivery of drugs: Barriers and models. J. Control. Release 2014, 190, 664–673. [CrossRef]
367. Alvarez-Lorenzo, C.; Concheiro, A. Smart drug delivery systems: From fundamentals to the clinic. Chem. Commun. 2014, 50, 7743–7765. [CrossRef]
368. Mitragotri, S.; Burke, P.A.; Langer, R. Overcoming the challenges in administering biopharmaceuticals: Formulation and delivery strategies. Nat. Rev. Drug Discov. 2014, 13, 655–672. [CrossRef]
369. Adepu, S.; Ramakrishna, S. Controlled Drug Delivery Systems: Current Status and Future Directions. Molecules 2021, 26, 5905. [CrossRef]
370. Bonadio, J.; Smiley, E.; Patil, P.; Goldstein, S. Localized, direct plasmid gene delivery in vivo: Prolonged therapy results in reproducible tissue regeneration. Nat. Med. 1999, 5, 753–759. [CrossRef]
371. Evans, C.H.; Robbins, P.D. Genetically Augmented Tissue Engineering of the Musculoskeletal System. Clin. Orthop. Relat. Res. 1999, 367, S410–S418. [CrossRef]
372. Bonadio, J.; A Goldstein, S.; Levy, R.J. Gene therapy for tissue repair and regeneration. Adv. Drug Deliv. Rev. 1998, 33, 53–69. [CrossRef]
373. Bonadio, J. Tissue engineering via local gene delivery. Klin. Wochenschr. 2000, 78, 303–311.
374. Bonadio, J. Tissue engineering via local gene delivery: Update and future prospects for enhancing the technology. Adv. Drug Deliv. Rev. 2000, 44, 185–194. [CrossRef]
375. Jang, J.-H.; Houchin, T.L.; Shea, L.D. Gene delivery from polymer scaffolds for tissue engineering. Expert Rev. Med. Devices 2004, 1, 127–138. [CrossRef]
376. De Laporte, L.; Shea, L.D. Matrices and scaffolds for DNA delivery in tissue engineering. Adv. Drug Deliv. Rev. 2007, 59, 292–307. [CrossRef]
377. Evans, C.H.; Ghivizzani, S.C.; Robbins, P.D. Orthopedic Gene Therapy in 2008. Mol. Ther. 2009, 17, 231–244. [CrossRef]
378. Evans, C.H. Advances in Regenerative Orthopedics. Mayo Clin. Proc. 2013, 88, 1323–1339. [CrossRef]
379. Gower, R.M.; Shea, L.D. Biomaterial Scaffolds for Controlled, Localized Gene Delivery of Regenerative Factors. Adv. Wound Care 2013, 2, 100–106. [CrossRef]
380. Smith, B.D.; Grande, D.A. The current state of scaffolds for musculoskeletal regenerative applications. Nat. Rev. Rheumatol. 2015, 11, 213–222. [CrossRef] [PubMed]
381. Evans, C.H.; Hubbard, J. Gene therapy approaches to regenerating the musculoskeletal system. Nat. Rev. Rheumatol. 2015, 11, 234–242. [CrossRef] [PubMed]
382. Lee, K.; Silva, E.A.; Mooney, D.J. Growth factor delivery-based tissue engineering: General approaches and a review of recent developments. J. R. Soc. Interface 2011, 8, 153–170. [CrossRef] [PubMed]
383. Liechty, W.B.; Kryscio, D.R.; Mooney, D.V.; Peppas, N.A. Polymers for drug delivery systems. Annu. Rev. Chem. Biomol. Eng. 2010, 1, 149–173. [CrossRef] [PubMed]
384. Thou, Y.; Zhu, C.; Wu, Y.F.; Zhang, L.; Tang, J.B. Effective modulation of transforming growth factor-beta1 expression through engineered microRNA-based plasmid-loaded nanospheres. Cytotherapy 2015, 17, 320–329. [CrossRef] [PubMed]
385. Qin, J.; Hou, Z.-Q.; Wang, H.; Wang, X.-L.; Liu, Y.-Y.; Gao, X.-H.; Lin, Y.-J.; Huang, B.-H. Effects of gene-activated matrix on autograft healing of anterior cruciate ligament. Mol. Med. Rep. 2013, 7, 679–683. [CrossRef]
386. Wu, G.; Sun, B.; Zhao, C.; Wang, Z.; Teng, S.; Yang, M.; Cui, Z.; Zhu, G.; Yu, Y. Three-dimensional tendon scaffold loaded with TGF-beta1 gene silencing plasmid prevents tendon adhesion and promotes tendon repair. ACS Biomater. Sci. Eng. 2021, 7, 5739–5748. [CrossRef]
387. Basile, P.; Dadali, T.; Jacobson, J.; Hasslund, S.; Ulrich-Vinther, M.; Söballe, K.; Nishio, Y.; Drissi, M.H.; Langstein, H.N.; Mitten, D.J.; et al. Freeze-dried Tendon Allografts as Tissue-engineering Scaffolds for Gdf5 Gene Delivery. Mol. Ther. 2008, 16, 466–473. [CrossRef] [PubMed]
388. Hasslund, S.; Dadali, T.; Ulrich-Vinther, M.; Söballe, K.; Schwarz, E.M.; A Awad, H. Freeze-dried allograft-mediated gene or protein delivery of growth and differentiation factor 5 reduces reconstructed murine flexor tendon adhesions. J. Tissue Eng. 2014, 5, 204173141528736. [CrossRef]
389. Shoji, T.; Nakasa, T.; Yamasaki, K.; Kodama, A.; Miyaki, S.; Niimoto, T.; Okuhara, A.; Kamei, N.; Adachi, N.; Ochi, M. The Effect of Intra-articular Injection of MicroRNA-210 on Ligament Healing in a Rat Model. Am. J. Sport. Med. 2012, 40, 2470–2478. [CrossRef]
390. Usman, M.A.; Nakasa, T.; Shoji, T.; Kato, T.; Kawanishi, Y.; Hamanishi, M.; Kamei, N.; Ochi, M. The effect of administration of double stranded MicroRNA-210 on acceleration of Achilles tendon healing in a rat model. J. Orthop. Sci. 2015, 20, 538–546. [CrossRef]
391. Sakti, M.; Nakasa, T.; Shoji, T.; Usman, M.A.; Kawanishi, Y.; Hamanishi, M.; Yusuf, I.; Ochi, M. Acceleration of healing of the medial collateral ligament of the knee by local administration of synthetic microRNA-210 in a rat model. Asia-Pac. J. Sport. Med. Arthrosoc. Rehabil. Technol. 2015, 2, 129–136. [CrossRef]
392. Ginn, S.L.; Amaya, A.K.; Alexander, I.E.; Edelstein, M.; Abedi, M.R. Gene therapy clinical trials worldwide to 2017: An update. J. Gene Med. 2018, 20, e3015. [CrossRef]
393. Evans, C.H.; Ghivizzani, S.C.; Robbins, P.D. Arthritis gene therapy is becoming a reality. Nat. Rev. Rheumatol. 2018, 14, 381–382. [CrossRef]
394. Watson-Levings, R.S.; Palmer, G.D.; Levings, P.P.; Dacanay, E.A.; Evans, C.H.; Ghivizzani, S.C. Gene Therapy in Orthopaedics: Progress and Challenges in Pre-Clinical Development and Translation. *Front. Bioeng. Biotechnol.* 2022, 10, 901317. [CrossRef]

395. Murphy, S.V.; Atala, A. 3D bioprinting of tissues and organs. *Nat. Biotechnol.* 2014, 32, 773–785. [CrossRef]

396. Park, S.H.; Choi, Y.-J.; Moon, S.W.; Lee, B.H.; Shim, J.-H.; Cho, D.-W.; Wang, J.H. Three-Dimensional Bio-Printed Scaffold Sleeves with Mesenchymal Stem Cells for Enhancement of Tendon-to-Bone Healing in Anterior Cruciate Ligament Reconstruction Using Soft-Tissue Tendon Graft. *Arthrosc. J. Arthrosc. Relat. Surg.* 2018, 34, 166–179. [CrossRef]

397. Cunniffe, G.M.; Gonzalez-Fernandez, T.; Daly, A.; Sathy, B.N.; Jeon, O.; Alsberg, E.; Kelly, D. Three-Dimensional Bioprinting of Polycaprolactone Reinforced Gene Activated Bioinks for Bone Tissue Engineering. *Tissue Eng. Part A* 2017, 23, 891–900. [CrossRef]

398. Potyondy, T.; Uquillas, J.A.; Tebon, P.J.; Byambaa, B.; Hasan, A.; Tavafoghi, M.; Mary, H.; Aninwene, G.E.; Pountos, I.; Khademhosseini, A.; et al. Recent advances in 3D bioprinting of musculoskeletal tissues. *Biofabrication* 2021, 13, 022001. [CrossRef]

399. Bakirci, E.; Guenat, O.; Ahmad, S.; Gantenbein, B. Tissue engineering approaches for the repair and regeneration of the anterior cruciate ligament: Towards 3D bioprinted ACL-on-chip. *Eur. Cells Mater.* 2022, 44, 21–42. [CrossRef]

400. Perez-Pinera, P.; Kocak, D.D.; Vockley, C.M.; Adler, A.F.; Kabadi, A.M.; Polstein, L.R.; Thakore, P.I.; Glass, K.A.; Ousterout, D.G.; Leong, K.W.; et al. RNA-guided gene activation by CRISPR-Cas9-based transcription factors. *Nat. Methods* 2013, 10, 973–976. [CrossRef]

401. Almarza, D.; Cucchiarini, M.; Loughlin, J. Genome editing for human osteoarthritis—A perspective. *Osteoarthr. Cartil.* 2017, 25, 1195–1198. [CrossRef] [PubMed]

402. Brunger, J.M.; Zutshi, A.; Willard, V.P.; Gersbach, C.A.; Guilak, F. CRISPR/Cas9 Editing of Murine Induced Pluripotent Stem Cells for Engineering Inflammation-Resistant Tissues. *Arthritis Rheumatol.* 2017, 69, 1111–1121. [CrossRef] [PubMed]

403. Brunger, J.M.; Zutshi, A.; Willard, V.P.; Gersbach, C.A.; Guilak, F. Genome Engineering of Stem Cells for Autonomously Regulated, Closed-Loop Delivery of Biologic Drugs. *Stem Cell Rep.* 2017, 8, 1202–1213. [CrossRef] [PubMed]

404. Choi, Y.-R.; Collins, K.H.; Lee, J-W.; Kang, H.-J.; Guilak, F. Genome Engineering for Osteoarthritis: From Designer Cells to Disease-Modifying Drugs. *Tissue Eng. Regen. Med.* 2019, 16, 335–343. [CrossRef]

405. Choi, Y.-R.; Collins, K.H.; Springer, L.E.; Pferdehirt, L.; Ross, A.K.; Wu, C.-L.; Moutos, F.T.; Harasymowicz, N.S.; Brunger, J.M.; Pham, C.T.N.; et al. A genome-engineered bioartificial implant for autoregulated anticytokine drug delivery. *Sci. Adv.* 2021, 7, eabj1414. [CrossRef]

406. Doudna, J.A.; Charpentier, E. The new frontier of genome engineering with CRISPR-Cas9. *Science* 2014, 346, 1258096. [CrossRef]

407. Farhang, N.; Brunger, J.M.; Stover, J.D.; Thakore, P.I.; Lawrence, B.; Guilak, F.; Gersbach, C.A.; Setton, L.A.; Bowles, R.D. CRISPR-Based Epigenome Editing of Cytokine Receptors for the Promotion of Cell Survival and Tissue Deposition in Inflammatory Environments. *Tissue Eng. Part A* 2017, 23, 738–749. [CrossRef]

408. Guilak, F.; Pferdehirt, L.; Ross, A.K.; Choi, Y.; Collins, K.H.; Nims, R.J.; Katz, D.B.; Klimak, M.; Tabbaa, S.; Pham, C.T.N. Designer Stem Cells: Genome Engineering and the Next Generation of Cell-Based Therapies. *J. Orthop. Res.* 2019, 37, 1287–1293. [CrossRef]

409. Klimak, M.; Nims, R.J.; Pferdehirt, L.; Collins, K.H.; Harasymowicz, N.S.; Oswald, S.J.; Setton, L.A.; Guilak, F. Immuoneengineering the next generation of arthritis therapies. *Acta Biomater.* 2021, 133, 74–86. [CrossRef]